Keywords
Last Name

Haralambos P. Gavras, MD

TitleEmeritus Professor
InstitutionBoston University School of Medicine
DepartmentMedicine
DivisionHypertension
Address700 Albany St Ctr for Adv Biomed Res
Boston MA 02118
Phone(617) 638-4025
Other Positions
TitleGraduate Faculty (Primary Mentor of Grad Students)
InstitutionBoston University School of Medicine, Division of Graduate Medical Sciences

 Research Expertise & Professional Interests
Expertise includes: Clinical studies; Experimental animal research; Basic research (molecular genetics of hypertension).

 NIH RePORTER Grants

Yr Title Project-Sub Proj Pubs
2008 BRADYKININ IN CARDIOVASCULAR DISEASE 5P41RR010888-12-5304 236
2007 BRADYKININ IN CARDIOVASCULAR DISEASE 2P41RR010888-11-8125 236
2006 Bradykinin in Cardiovascular Disease 5R01HL058807-08 10
2005 Bradykinin in Cardiovascular Disease 5R01HL058807-07 10
2005 IDENTIFYING GENES IN ABNORMAL BLOOD PRESSURE 5P50HL055001-10 37
2005 IDENTIFYING GENES INVOLVED IN ABNORMAL BLOOD PRESSURE 5P50HL055001-10-1 37
2005 CORE B--ANIMAL 5P50HL055001-10-9001 37
2004 IDENTIFYING GENES INVOLVED IN ABNORMAL BLOOD PRESSURE 5P50HL055001-09-1 37
2004 CORE B--ANIMAL 5P50HL055001-09-9001 37
2004 CORE A-- ADMINISTRATIVE CORE 5P50HL055001-09-5974 37
Showing the 10 most recent of 58 results. Show All Results

 Self-Described Keywords
  • basic research
  • clinical research
  • hypertension
  • lectures
 Publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Kouremenos N, Zacharopoulou IV, Triantafyllidi H, Zacharopoulos GV, Mornos C, Filippatos G, Lekakis J, Kremastinos D, Manolis AI, Gavras H. Genes and genetic variations involved in the development of hypertension: focusing on a Greek patient cohort. Hellenic J Cardiol. 2014 Jan-Feb; 55(1):9-16. PMID: 24491930.
    View in: PubMed
  2. Marketou ME, Kintsurashvili E, Androulakis NE, Kontaraki J, Alexandrakis MG, Gavras I, Vardas PE, Gavras H. Blockade of platelet alpha2B-adrenergic receptors: a novel antiaggregant mechanism. Int J Cardiol. 2013 Oct 3; 168(3):2561-6. PMID: 23582690.
    View in: PubMed
  3. Gavras I, Gavras H. 'Volume-expanded' hypertension: the effect of fluid overload and the role of the sympathetic nervous system in salt-dependent hypertension. J Hypertens. 2012 Apr; 30(4):655-9. PMID: 22227820.
    View in: PubMed
  4. Koupenova M, Johnston-Cox H, Vezeridis A, Gavras H, Yang D, Zannis V, Ravid K. A2b adenosine receptor regulates hyperlipidemia and atherosclerosis. Circulation. 2012 Jan 17; 125(2):354-63. PMID: 22144568.
    View in: PubMed
  5. Manolis AJ, Marketou ME, Gavras I, Gavras H. Cardioprotective properties of bradykinin: role of the B(2) receptor. Hypertens Res. 2010 Aug; 33(8):772-7. PMID: 20505673.
    View in: PubMed
  6. Marketou M, Kintsurashvili E, Papanicolaou KN, Lucero HA, Gavras I, Gavras H. Cardioprotective effects of a selective B(2) receptor agonist of bradykinin post-acute myocardial infarct. Am J Hypertens. 2010 May; 23(5):562-8. PMID: 20186129.
    View in: PubMed
  7. McCalmon SA, Desjardins DM, Ahmad S, Davidoff KS, Snyder CM, Sato K, Ohashi K, Kielbasa OM, Mathew M, Ewen EP, Walsh K, Gavras H, Naya FJ. Modulation of angiotensin II-mediated cardiac remodeling by the MEF2A target gene Xirp2. Circ Res. 2010 Mar 19; 106(5):952-60. PMID: 20093629.
    View in: PubMed
  8. Lucero HA, Kintsurashvili E, Marketou ME, Gavras H. Cell signaling, internalization, and nuclear localization of the angiotensin converting enzyme in smooth muscle and endothelial cells. J Biol Chem. 2010 Feb 19; 285(8):5555-68. PMID: 20022959.
    View in: PubMed
  9. Ahmad S, Cesana F, Lamperti E, Gavras H, Yu J. Attenuation of angiotensin II-induced hypertension and cardiac hypertrophy in transgenic mice overexpressing a type 1 receptor mutant. Am J Hypertens. 2009 Dec; 22(12):1320-5. PMID: 19779471.
    View in: PubMed
  10. Kintsurashvili E, Shenouda S, Ona D, Ona L, Ahmad S, Ravid K, Gavras I, Gavras H. Hypertension in transgenic mice with brain-selective overexpression of the alpha(2B)-adrenoceptor. Am J Hypertens. 2009 Jan; 22(1):41-5. PMID: 18989257.
    View in: PubMed
  11. Silva VS, Martin LC, Franco RJ, Carvalho FC, Bregagnollo EA, Castro JH, Gavras I, Gavras H. Pleiotropic effects of statins may improve outcomes in atherosclerotic renovascular disease. Am J Hypertens. 2008 Oct; 21(10):1163-8. PMID: 18670414.
    View in: PubMed
  12. Duka A, Kintsurashvili E, Duka I, Ona D, Hopkins TA, Bader M, Gavras I, Gavras H. Angiotensin-converting enzyme inhibition after experimental myocardial infarct: role of the kinin B1 and B2 receptors. Hypertension. 2008 May; 51(5):1352-7. PMID: 18347228.
    View in: PubMed
  13. Gavras H, Brunner HR. Evolution and hypertension: is the Renin system necessary? Hypertension. 2007 Jun; 49(6):e36; author reply e37. PMID: 17389253.
    View in: PubMed
  14. Sun B, Kintsurashvili E, Ona D, Ignjacev-Lazich I, Gavras I, Gavras H. Inhibition of the alpha(1D)-adrenergic receptor gene by RNA interference (RNAi) in rat vascular smooth muscle cells and its effects on other adrenergic receptors. Vascul Pharmacol. 2007 May; 46(5):367-72. PMID: 17307398.
    View in: PubMed
  15. Cardoso de Carvalho F, Bregagnollo E, Santos Silva V, Brunie A, da Silva Franco RJ, Martin LC, Gavras I, Gavras H. Frequency of coronary artery disease in patients with renal artery stenosis without clinical manifestations of coronary insufficiency. Am J Hypertens. 2006 Nov; 19(11):1125-8. PMID: 17070422.
    View in: PubMed
  16. Shenouda SM, Johns C, Kintsurashvili E, Gavras I, Gavras H. Long-term inhibition of the central alpha(2B)-adrenergic receptor gene via recombinant AAV-delivered antisense in hypertensive rats. Am J Hypertens. 2006 Nov; 19(11):1135-43. PMID: 17070424.
    View in: PubMed
  17. Martin LC, Franco RJ, Gavras I, Matsubara BB, Okoshi K, Zanati SG, Caramori JT, Barretti P, Balbi AL, Gavras H. Is 44-hour better than 24-hour ambulatory blood pressure monitoring in hemodialysis? Kidney Blood Press Res. 2006; 29(5):273-9. PMID: 17035712.
    View in: PubMed
  18. Brunner HR, Gavras H. Validation of in-vitro data by in-vivo evidence: the example of angiotensin (1-7). J Hypertens. 2006 Oct; 24(10):1919-20. PMID: 16957547.
    View in: PubMed
  19. Yang D, Zhang Y, Nguyen HG, Koupenova M, Chauhan AK, Makitalo M, Jones MR, St Hilaire C, Seldin DC, Toselli P, Lamperti E, Schreiber BM, Gavras H, Wagner DD, Ravid K. The A2B adenosine receptor protects against inflammation and excessive vascular adhesion. J Clin Invest. 2006 Jul; 116(7):1913-23. PMID: 16823489.
    View in: PubMed
  20. Ribeiro AB, Gavras H. Angiotensin II antagonists: clinical experience in the treatment of hypertension, prevention of cardiovascular outcomes and renal protection in diabetic nephropathy and proteinuria. Arq Bras Endocrinol Metabol. 2006 Apr; 50(2):327-33. PMID: 16767299.
    View in: PubMed
  21. Triantafyllidi H, Kintsurashvili E, Johns C, Gavras I, Gavras H. Central plasmid antisense administration reduces blood pressure inhibiting alpha2B adrenoceptor gene expression in spontaneously hypertensive rats in vivo. Hellenic J Cardiol. 2006 May-Jun; 47(3):144-9. PMID: 16862820.
    View in: PubMed
  22. Duka A, Schwartz F, Duka I, Johns C, Melista E, Gavras I, Gavras H. A novel gene (Cmya3) induced in the heart by angiotensin II-dependent but not salt-dependent hypertension in mice. Am J Hypertens. 2006 Mar; 19(3):275-81. PMID: 16500513.
    View in: PubMed
  23. Duka A, Duka I, Gao G, Shenouda S, Gavras I, Gavras H. Role of bradykinin B1 and B2 receptors in normal blood pressure regulation. Am J Physiol Endocrinol Metab. 2006 Aug; 291(2):E268-74. PMID: 16507603.
    View in: PubMed
  24. Nguyen GH, Nguyen NC, Storm N, Gange C, Gavras H, Smith CL. Targeted cDNA differential display (TcDD). Biomol Eng. 2006 Mar; 23(1):41-54. PMID: 16466965.
    View in: PubMed
  25. Ignjacev-Lazich I, Kintsurashvili E, Johns C, Vitseva O, Duka A, Shenouda S, Gavras I, Gavras H. Angiotensin-converting enzyme regulates bradykinin receptor gene expression. Am J Physiol Heart Circ Physiol. 2005 Nov; 289(5):H1814-20. PMID: 16219810.
    View in: PubMed
  26. Russo CJ, Melista E, Cui J, DeStefano AL, Bakris GL, Manolis AJ, Gavras H, Baldwin CT. Association of NEDD4L ubiquitin ligase with essential hypertension. Hypertension. 2005 Sep; 46(3):488-91. PMID: 16103266.
    View in: PubMed
  27. Larkin JE, Frank BC, Gavras H, Sultana R, Quackenbush J. Independence and reproducibility across microarray platforms. Nat Methods. 2005 May; 2(5):337-44. PMID: 15846360.
    View in: PubMed
  28. Standridge JB, Sealey JE, Laragh JH, Houston MC, Gavras H, Johnson RJ, Blumenfeld JD, Brown M, Egan BM, Meltzer JI, Shimosawa T, Fujita T. A free-ranging roundtable discussion on hypertension. J Hum Hypertens. 2005 Apr; 19(4):259-66. PMID: 15716983.
    View in: PubMed
  29. Kintsurashvili E, Duka A, Ignjacev I, Pattakos G, Gavras I, Gavras H. Age-related changes of bradykinin B1 and B2 receptors in rat heart. Am J Physiol Heart Circ Physiol. 2005 Jul; 289(1):H202-5. PMID: 15708952.
    View in: PubMed
  30. Gavras H. Report on the fifth annual Laragh conference: Interaction of the angiotensin converting enzyme (ACE) with the renin-angiotensin system, the kinin system and beyond. Am J Hypertens. 2005 Jan; 18(1):1-2. PMID: 15691609.
    View in: PubMed
  31. Manolis AJ, Iraklianou S, Pittaras A, Zaris M, Tsioufis K, Psaltiras G, Psomali D, Foussas S, Gavras I, Gavras H. Arterial compliance changes in diabetic normotensive patients after angiotensin-converting enzyme inhibition therapy. Am J Hypertens. 2005 Jan; 18(1):18-22. PMID: 15691612.
    View in: PubMed
  32. Zhou XF, Cui J, DeStefano AL, Chazaro I, Farrer LA, Manolis AJ, Gavras H, Baldwin CT. Polymorphisms in the promoter region of catalase gene and essential hypertension. Dis Markers. 2005; 21(1):3-7. PMID: 15735318.
    View in: PubMed
  33. Cui J, Melista E, Chazaro I, Zhang Y, Zhou X, Manolis AJ, Baldwin CT, Destefano AL, Gavras H. Sequence variation of bradykinin receptors B1 and B2 and association with hypertension. J Hypertens. 2005 Jan; 23(1):55-62. PMID: 15643125.
    View in: PubMed
  34. Handy DE, Gavras H . Hypertension and atherogenesis. In: Molecular Mechanisms of Atherosclerosis. Joseph Loscalzo, editor. Taylor & Francis. Abingdon, Oxon, UK. 2005; 195-207.
  35. Gavras I, Gavras H. The debate goes on--what is your choice? Am J Cardiol. 2005 Jan 1; 95(1):53-4. PMID: 15619394.
    View in: PubMed
  36. Gavras I, Gavras H. ACE Inhibitor Trials: Effects in Hypertension. In: Hypertension: A companion to Brenner and Rectors the kidney, second edition. Editors: Suzanne Oparil, Michael A. Weber. Elsevier Saunders. Philadelphia, PA. 2005; 388-390.
  37. Martin LC, Franco RJ, Gavras I, Matsubara BB, Garcia S, Caramori JT, Barretti BB, Balbi AL, Barsanti R, Padovani C, Gavras H. Association between hypervolemia and ventricular hypertrophy in hemodialysis patients. Am J Hypertens. 2004 Dec; 17(12 Pt 1):1163-9. PMID: 15607624.
    View in: PubMed
  38. Brunner DB, Desponds G, Biollaz J, Keller I, Ferber F, Gavras H, Brunner HR, Schelling JL. Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects. 1981. Br J Clin Pharmacol. 2004 Dec; 58(7):S778-84; discussion S785-7. PMID: 15595971.
    View in: PubMed
  39. Larkin JE, Frank BC, Gaspard RM, Duka I, Gavras H, Quackenbush J. Cardiac transcriptional response to acute and chronic angiotensin II treatments. Physiol Genomics. 2004 Jul 8; 18(2):152-66. PMID: 15126644.
    View in: PubMed
  40. Schwartz F, Duka A, Duka I, Cui J, Gavras H. Novel targets of ANG II regulation in mouse heart identified by serial analysis of gene expression. Am J Physiol Heart Circ Physiol. 2004 Nov; 287(5):H1957-66. PMID: 15242839.
    View in: PubMed
  41. Schwartz F, Duka A, Sun F, Cui J, Manolis A, Gavras H. Mitochondrial genome mutations in hypertensive individuals. Am J Hypertens. 2004 Jul; 17(7):629-35. PMID: 15233983.
    View in: PubMed
  42. Gavras I, Gavras H. Hypertension, vasoactive peptides and coagulation factors. J Hypertens. 2004 Jun; 22(6):1091-2. PMID: 15167441.
    View in: PubMed
  43. DiPetrillo K, Tsaih SW, Sheehan S, Johns C, Kelmenson P, Gavras H, Churchill GA, Paigen B. Genetic analysis of blood pressure in C3H/HeJ and SWR/J mice. Physiol Genomics. 2004 Apr 13; 17(2):215-20. PMID: 14996992.
    View in: PubMed
  44. Elijovich F, Laffer CL, Schiffrin EL, Gavras H, Amador E. Endothelin-aldosterone interaction and proteinuria in low-renin hypertension. J Hypertens. 2004 Mar; 22(3):573-82. PMID: 15076164.
    View in: PubMed
  45. Gavras H. The discovery of captopril: reply. FASEB J. 2004 Feb; 18(2):225. PMID: 14769815.
    View in: PubMed
  46. Gavras H. Adrenergic receptors in hypertension and heart failure. Am J Hypertens. 2004 Jan; 17(1):98-9. PMID: 14700521.
    View in: PubMed
  47. Gavras I, Gavras H . Progress in stroke prevention: Lessons from the lastest trials. Cardiovasc Rev & Reports. 2004; 25:229-231.
  48. Triantafyllidi E, Baldwin C, Schwartz F, Gavras H. Study of hypertension in spantaneous hypertensive rats by sequecing the genomic DNA of alpha2B receptors. Hellenic J Cardiol. 2004; 45:65-70.
  49. Schwartz F, Gavras H. Genetics of Human Essential Hypertension – Review. Rev Bras Hipertens. 2004; 11:88-93.
  50. Schwartz F, Duka A, Triantafyllidi E, Johns C, Duka I, Cui J, Gavras H. Serial analysis of gene expression in mouse kidney following angiotensin II administration. Physiol Genomics. 2003 Dec 16; 16(1):90-8. PMID: 14570981.
    View in: PubMed
  51. Voudris V, Avramides D, Gatzov P, Malakos J, Skoularigis J, Manolis A, Gavras H, Gavras I, Cokkinos DV. The effect of rapid decreases of blood pressure by different mechanisms on coronary flow and flow reserve in normal coronary arteries. Am J Hypertens. 2003 Dec; 16(12):1000-5. PMID: 14643572.
    View in: PubMed
  52. Duka I, Duka A, Kintsurashvili E, Johns C, Gavras I, Gavras H. Mechanisms mediating the vasoactive effects of the B1 receptors of bradykinin. Hypertension. 2003 Nov; 42(5):1021-5. PMID: 14557281.
    View in: PubMed
  53. Cui J, Zhou X, Chazaro I, DeStefano AL, Manolis AJ, Baldwin CT, Gavras H. Association of polymorphisms in the promoter region of the PNMT gene with essential hypertension in African Americans but not in whites. Am J Hypertens. 2003 Oct; 16(10):859-63. PMID: 14553966.
    View in: PubMed
  54. Kintsurashvili E, Johns C, Ignjacev I, Gavras I, Gavras H. Central alpha2B-adrenergic receptor antisense in plasmid vector prolongs reversal of salt-dependent hypertension. J Hypertens. 2003 May; 21(5):961-7. PMID: 12714871.
    View in: PubMed
  55. Sun F, Cui J, Gavras H, Schwartz F. A novel class of tests for the detection of mitochondrial DNA-mutation involvement in diseases. Am J Hum Genet. 2003 Jun; 72(6):1515-26. PMID: 12730827.
    View in: PubMed
  56. Erlich PM, Cui J, Chazaro I, Farrer LA, Baldwin CT, Gavras H, DeStefano AL. Genetic variants of WNK4 in whites and African Americans with hypertension. Hypertension. 2003 Jun; 41(6):1191-5. PMID: 12719438.
    View in: PubMed
  57. Gavras I, Gavras H. Are patients who develop angioedema with ACE inhibition at risk of the same problem with AT1 receptor blockers? Arch Intern Med. 2003 Jan 27; 163(2):240-1. PMID: 12546617.
    View in: PubMed
  58. Gavras H. Inappropriate attribution: the "Lazy Author Syndrome". Am J Hypertens. 2002 Sep; 15(9):831. PMID: 12722775.
    View in: PubMed
  59. Gavras I, Gavras H. Angiotensin II as a cardiovascular risk factor. J Hum Hypertens. 2002 May; 16 Suppl 2:S2-6. PMID: 11967726.
    View in: PubMed
  60. Brunner HR, Gavras H. Angiotensin blockade for hypertension: a promise fulfilled. Lancet. 2002 Mar 23; 359(9311):990-2. PMID: 11937175.
    View in: PubMed
  61. Gavras I, Gavras H . Angiotensin blockers in the treatment of hypertension. In: Harrison's Advances in Cardiology. Eugene Braunwald, ed. McGraw-Hill. 2002; 75-79.
  62. Gavras I, Gavras H. Metabolic effects of angiotensin-converting enzyme inhibition: the role of bradykinin. Current Opinion in Endocrinology & Diabetes. 2002; 9:323-328.
  63. Monteagudo PT, Gavras H, Gavras I, Kohlmann O, Ribeiro AB, Zanella MT. Role of vasopressin in 24-hour blood pressure regulation in diabetic patients with autonomic neuropathy. Am J Hypertens. 2002 Jan; 15(1 Pt 1):42-7. PMID: 11824859.
    View in: PubMed
  64. Gavras, Gavras H. . Angiotensin-converting enzyme/kininase II: hemodynamic and metabolic effects. Greek Nephrology. 2002; 14:445-448.
  65. Duka I, Shenouda S, Johns C, Kintsurashvili E, Gavras I, Gavras H. Role of the B(2) receptor of bradykinin in insulin sensitivity. Hypertension. 2001 Dec 1; 38(6):1355-60. PMID: 11751717.
    View in: PubMed
  66. Gavras I, Manolis AJ, Gavras H. The alpha2 -adrenergic receptors in hypertension and heart failure: experimental and clinical studies. J Hypertens. 2001 Dec; 19(12):2115-24. PMID: 11725152.
    View in: PubMed
  67. Kintsurashvili E, Gavras I, Johns C, Gavras H. Effects of antisense oligodeoxynucleotide targeting of the alpha(2B)-adrenergic receptor messenger RNA in the central nervous system. Hypertension. 2001 Nov; 38(5):1075-80. PMID: 11711500.
    View in: PubMed
  68. Kintsurashvili E, Duka I, Gavras I, Johns C, Farmakiotis D, Gavras H. Effects of ANG II on bradykinin receptor gene expression in cardiomyocytes and vascular smooth muscle cells. Am J Physiol Heart Circ Physiol. 2001 Oct; 281(4):H1778-83. PMID: 11557571.
    View in: PubMed
  69. Stefanadis C, Manolis A, Dernellis J, Tsioufis C, Tsiamis E, Gavras I, Gavras H, Toutouzas P. Acute effect of clonidine on left ventricular pressure-volume relation in hypertensive patients with diastolic heart dysfunction. J Hum Hypertens. 2001 Sep; 15(9):635-42. PMID: 11550110.
    View in: PubMed
  70. DeStefano AL, Gavras H, Heard-Costa N, Bursztyn M, Manolis A, Farrer LA, Baldwin CT, Gavras I, Schwartz F. Maternal component in the familial aggregation of hypertension. Clin Genet. 2001 Jul; 60(1):13-21. PMID: 11531965.
    View in: PubMed
  71. Gavras HP. Issues in hypertension: drug tolerability and special populations. Am J Hypertens. 2001 Jul; 14(7 Pt 2):231S-236S. PMID: 11459211.
    View in: PubMed
  72. Gavras I, Gavras H. Role of alpha2-adrenergic receptors in hypertension. Am J Hypertens. 2001 Jun; 14(6 Pt 2):171S-177S. PMID: 11411753.
    View in: PubMed
  73. Duka I, Kintsurashvili E, Gavras I, Johns C, Bresnahan M, Gavras H. Vasoactive potential of the b(1) bradykinin receptor in normotension and hypertension. Circ Res. 2001 Feb 16; 88(3):275-81. PMID: 11179194.
    View in: PubMed
  74. Gavras H, Brunner HR. Role of angiotensin and its inhibition in hypertension, ischemic heart disease, and heart failure. Hypertension. 2001 Feb; 37(2 Pt 2):342-5. PMID: 11230297.
    View in: PubMed
  75. Elijovich F, Laffer CL, Amador E, Gavras H, Bresnahan MR, Schiffrin EL. Regulation of plasma endothelin by salt in salt-sensitive hypertension. Circulation. 2001 Jan 16; 103(2):263-8. PMID: 11208687.
    View in: PubMed
  76. Gavras I, Gavras H. The role of ACE inhibition in heart failure. In: ACE Inhibitors, editors: Pedro D'Orleans-Juste, Gerard E. Plante. Birkhauser Verlag. Basel, Switzerland. 2001; 71-79.
  77. Gavras I, Gavras H. Benefits and side effects of blood pressure lowering treatment: what was wrong with doxazosin in the ALLHAT? Curr Control Trials Cardiovasc Med. 2001; 2(6):257-259. PMID: 11806808.
    View in: PubMed
  78. Gavras I, Gavras H . Role of angiotensin-converting enzyme (ACE) in the pathophysiology of hypertension. In: Angiotensin-Converting Enzyme (ACE): Clinical and Experimental Insights. Editor: Thomas D. Giles. Health Care Communications, Inc. Fort Lee, NJ. 2001; 123-126.
  79. Sugiyama F, Churchill GA, Higgins DC, Johns C, Makaritsis KP, Gavras H, Paigen B. Concordance of murine quantitative trait loci for salt-induced hypertension with rat and human loci. Genomics. 2001 Jan 1; 71(1):70-7. PMID: 11161799.
    View in: PubMed
  80. Levy D, DeStefano AL, Larson MG, O'Donnell CJ, Lifton RP, Gavras H, Cupples LA, Myers RH. Evidence for a gene influencing blood pressure on chromosome 17. Genome scan linkage results for longitudinal blood pressure phenotypes in subjects from the framingham heart study. Hypertension. 2000 Oct; 36(4):477-83. PMID: 11040222.
    View in: PubMed
  81. Gavras H. Effect of ramipril on cardiovascular events in high-risk patients. N Engl J Med. 2000 Jul 6; 343(1):65-6. PMID: 10896546.
    View in: PubMed
  82. Gavras I, Gavras H. The antiarrhythmic potential of angiotensin II antagonism: experience with losartan. Am J Hypertens. 2000 May; 13(5 Pt 1):512-7. PMID: 10826402.
    View in: PubMed
  83. Zhao Z, Makaritsis K, Francis CE, Gavras H, Ravid K. A role for the A3 adenosine receptor in determining tissue levels of cAMP and blood pressure: studies in knock-out mice. Biochim Biophys Acta. 2000 Mar 17; 1500(3):280-90. PMID: 10699369.
    View in: PubMed
  84. Duka I, Gavras I, Johns C, Handy DE, Gavras H. Role of the postsynaptic alpha(2)-adrenergic receptor subtypes in catecholamine-induced vasoconstriction. Gen Pharmacol. 2000 Feb; 34(2):101-6. PMID: 10974417.
    View in: PubMed
  85. Makaritsis KP, Johns C, Gavras I, Gavras H. Role of alpha(2)-adrenergic receptor subtypes in the acute hypertensive response to hypertonic saline infusion in anephric mice. Hypertension. 2000 Feb; 35(2):609-13. PMID: 10679505.
    View in: PubMed
  86. Nicolaou M, DeStefano AL, Gavras I, Cupples LA, Manolis AJ, Baldwin CT, Gavras H, Farrer LA. Genetic predisposition to stroke in relatives of hypertensives. Stroke. 2000 Feb; 31(2):487-92. PMID: 10657427.
    View in: PubMed
  87. Gavras H, Gavras I . Cardiac effects of angiotensin II and AT1 receptor blockade. In: Angiotensin II Receptor Antagonists. Eds.: Epstein M, Brunner HR. Hanley & Belfus, Inc. Philadelphia, PA. 2000; 215-222.
  88. Gavras H. Update on the clinical pharmacology of candesartan cilexetil. Am J Hypertens. 2000 Jan; 13(1 Pt 2):25S-30S. PMID: 10678285.
    View in: PubMed
  89. Gavras H, Gavras I. Commentary: Implications for the pathophysiology of hypertension and heart failure derived from clinical experience with drugs modifying the renin-angiotensin system. In Drugs, Enzymes and Receptors of the Renin-Angiotensin System: Celebrating a Century of Discovery. Eds: Husain A, Graham RM. Harwood Academic Publishers. Amsterdam,The Netherlands. 2000; 187-190.
  90. Brunner HR, Gavras H. Early experience with angiotensin II recepor antagonists and angiotensin-converting enzyme inhibitors. In: Angiotensin II Receptor Antagonists. Eds.: Epstein M, Brunner HR. Hanley & Belfus, Inc. Philadephia, PA. 2000; 79-87.
  91. Gavras I, Gavras H . The role of AII antagonists in hypertension: Focus on telmisartan. Cardiovascular Reviews and Reports. 2000; 21:76-80.
  92. Gavras I, Manolis AJ, Gavras H. The economics of therapeutic advances: the paradigm of sympathetic suppression in chronic heart failure. Arch Intern Med. 1999 Dec 13-27; 159(22):2634-6. PMID: 10597753.
    View in: PubMed
  93. Schwartz F, Baldwin CT, Baima J, Gavras H. Mitochondrial DNA mutations in patients with orthostatic hypotension. Am J Med Genet. 1999 Sep 10; 86(2):145-50. PMID: 10449650.
    View in: PubMed
  94. Makaritsis KP, Johns C, Gavras I, Altman JD, Handy DE, Bresnahan MR, Gavras H. Sympathoinhibitory function of the alpha(2A)-adrenergic receptor subtype. Hypertension. 1999 Sep; 34(3):403-7. PMID: 10489385.
    View in: PubMed
  95. Baldwin CT, Schwartz F, Baima J, Burzstyn M, DeStefano AL, Gavras I, Handy DE, Joost O, Martel T, Manolis A, Nicolaou M, Bresnahan M, Farrer L, Gavras H. Identification of a polymorphic glutamic acid stretch in the alpha2B-adrenergic receptor and lack of linkage with essential hypertension. Am J Hypertens. 1999 Sep; 12(9 Pt 1):853-7. PMID: 10509541.
    View in: PubMed
  96. Baima J, Nicolaou M, Schwartz F, DeStefano AL, Manolis A, Gavras I, Laffer C, Elijovich F, Farrer L, Baldwin CT, Gavras H. Evidence for linkage between essential hypertension and a putative locus on human chromosome 17. Hypertension. 1999 Jul; 34(1):4-7. PMID: 10406815.
    View in: PubMed
  97. Gavras I, Gavras H. Safety and tolerability of eprosartan. Pharmacotherapy. 1999 Apr; 19(4 Pt 2):102S-107S. PMID: 10213529.
    View in: PubMed
  98. Gavras I, Manolis A, Gavras H. Genetic epidemiology of essential hypertension. J Hum Hypertens. 1999 Apr; 13(4):225-9. PMID: 10333339.
    View in: PubMed
  99. Gavras H. Historical evolution of angiotensin II receptor blockers: therapeutic advantages. J Am Soc Nephrol. 1999 Apr; 10 Suppl 12:S255-7. PMID: 10201879.
    View in: PubMed
  100. Gavras I, Gavras H. Effects of eprosartan versus enalapril in hypertensive patients on the renin-angiotensin-aldosterone system and safety parameters: results from a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group. Curr Med Res Opin. 1999; 15(1):15-24. PMID: 10216807.
    View in: PubMed
  101. Gavras H, Gavras I . The renin-angiotensin system and the heart. In: Contemporary Endocrinology: Hormones and the Heart in Health and Disease. Ed.: Share L. Humana Press Inc. Totowa, NJ. 1999; 63-67.
  102. Gavras H, Gavras I. Bioactive peptides in the treatment of hypertension and heart failure. In: Bioactive Peptides in Drug Discovery and Design: Medical Aspects. Eds.: Matsoukas J, Mavromoustakos T. IOS Press. Amsterdam, Netherlands. 1999; 41-50.
  103. Makaritsis KP, Handy DE, Johns C, Kobilka B, Gavras I, Gavras H. Role of the alpha2B-adrenergic receptor in the development of salt-induced hypertension. Hypertension. 1999 Jan; 33(1):14-7. PMID: 9931075.
    View in: PubMed
  104. Manolis AJ, Tsalopoulos E, Ramos C, Katsaros K, Dalabiras P, Hatzissavas J, Foussas S, Gavras I, Bresnahan M, Gavras H. Benefits of central sympathetic suppression with clonidine after acute myocardial infarction. Advances in Therapy. 1999; 16:272-282.
  105. Makaritsis KP, Gavras H, Du Y, Chobanian AV, Brecher P. Alpha1-adrenergic plus angiotensin receptor blockade reduces atherosclerosis in apolipoprotein E-deficient mice. Hypertension. 1998 Dec; 32(6):1044-8. PMID: 9856971.
    View in: PubMed
  106. DeStefano AL, Baldwin CT, Burzstyn M, Gavras I, Handy DE, Joost O, Martel T, Nicolaou M, Schwartz F, Streeten DH, Farrer LA, Gavras H. Autosomal dominant orthostatic hypotensive disorder maps to chromosome 18q. Am J Hum Genet. 1998 Nov; 63(5):1425-30. PMID: 9792870.
    View in: PubMed
  107. Manolis AJ, Olympios C, Sifaki M, Smirnioudis N, Handanis S, Argirakis S, Katsaros C, Gavras I, Gavras H. Chronic sympathetic suppression in the treatment of chronic congestive heart failure. Clin Exp Hypertens. 1998 Oct; 20(7):717-31. PMID: 9764717.
    View in: PubMed
  108. Balbi AL, Franco RJ, Barretti P, Gavras I, Gavras H. Renal artery clipping attenuates the progression of adriamycin nephropathy. Am J Hypertens. 1998 Sep; 11(9):1124-8. PMID: 9752899.
    View in: PubMed
  109. Handy DE, Johns C, Bresnahan MR, Tavares A, Bursztyn M, Gavras H. Expression of alpha2-adrenergic receptors in normal and atherosclerotic rabbit aorta. Hypertension. 1998 Aug; 32(2):311-7. PMID: 9719060.
    View in: PubMed
  110. Manolis AJ, Beldekos D, Handanis S, Haralabidis G, Hatzissavas J, Foussas S, Cokkinos DV, Bresnahan M, Gavras I, Gavras H. Comparison of spirapril, isradipine, or combination in hypertensive patients with left ventricular hypertrophy: effects on LVH regression and arrhythmogenic propensity. Am J Hypertens. 1998 Jun; 11(6 Pt 1):640-8. PMID: 9657622.
    View in: PubMed
  111. Gavras I, Gavras H. The calcium channel antagonist controversy. Am Fam Physician. 1998 Apr 1; 57(7):1484, 1492. PMID: 9556636.
    View in: PubMed
  112. Gavras H, Chrysant SG, Niederman AL, Marbury TC, Goldstein R, Conradi E. Evaluation of enalapril combined with diltiazem ER in patients with stage 3-4 essential hypertension. Clin Exp Hypertens. 1998 Jan; 20(1):41-52. PMID: 9507787.
    View in: PubMed
  113. Gavras I, Gavras H. The renin-angiotensin system in hypertensive cardiac disease. In: Renin Angiotensin. Editors: Ulfendahl HR, Aurell M. Portland Press. London. 1998; 74:265-272.
  114. Gavras I, Gavras H. Salt in hypertension: physiological and molecular aspects. Recent Prog Horm Res. 1998; 53:1-6. PMID: 9769699.
    View in: PubMed
  115. Gavras H. Historical overview: blocking the renin-angiotensin system in heart failure. In: 100 years of the renin—angiotensin system. Eds.: Nicholls MG, Brunner HR, Ikram H, Charles S. Sweet and J. Findlay Walker. Hughes Associates. Hooper House, Oxford, UK. 1998; 43-45.
  116. Gavras H, Gavras I. Hypertension in the Elderly. Hormonal and Therapeutic Aspects. In: Recent Advances in Geriatrics, editors: Mario Barbagallo, Giuseppe Licata, James R. Sowers. Plenum Press. New York,NY. 1998; 69-74.
  117. Gavras H . Genetic Profiling in Hypertension. In: Hypertension Primer, Second Edition. Senior Editors: Joseph L. Izzo, Jr. and Henry R. Black. Lippincott Williams & Wilkins. Baltimore, MD. 1998; 306-307.
  118. Bakris GL, Kusmirek SL, Smith AC, Gavras I, Gavras H. Calcium antagonism abolishes the antipressor action of vasopressin (V1) receptor antagonism. Am J Hypertens. 1997 Oct; 10(10 Pt 1):1153-8. PMID: 9370387.
    View in: PubMed
  119. Chrysant SG, Gavras H, Niederman AL, Marbury TC, Goldstein R. Clinical utility of long-term enalapril/diltiazem ER in stage 3-4 essential hypertension. Long-term Use of Enalapril/Diltiazem ER in Stage 3-4 Hypertension Group. J Clin Pharmacol. 1997 Sep; 37(9):810-5. PMID: 9549634.
    View in: PubMed
  120. Manolis AJ, Beldekos D, Hatzissavas J, Foussas S, Cokkinos D, Bresnahan M, Gavras I, Gavras H. Hemodynamic and humoral correlates in essential hypertension: relationship between patterns of LVH and myocardial ischemia. Hypertension. 1997 Sep; 30(3 Pt 2):730-4. PMID: 9323014.
    View in: PubMed
  121. Bakris G, Bursztyn M, Gavras I, Bresnahan M, Gavras H. Role of vasopressin in essential hypertension: racial differences. J Hypertens. 1997 May; 15(5):545-50. PMID: 9170008.
    View in: PubMed
  122. Gavras I, Manolis A, Gavras H. Drug therapy for hypertension. Am Fam Physician. 1997 Apr; 55(5):1823-6, 1829-34. PMID: 9105208.
    View in: PubMed
  123. Gavras H . Commentary: A hypertension report card. In: Postgraduate Medicine, A special Report on Clinical Experience with Losartan, the first A-II blocker, in diverse hypertensive populations. Healthcare Information Programs, McGraw-Hill Healthcare Information Group. Minneapolis, MN. 1997; 7-12.
  124. Gavras H. Angiotensin II antagonism: a new avenue of hypertension management. Blood Press Suppl. 1997; 1:42-6. PMID: 9285108.
    View in: PubMed
  125. Gavras H. Introduction. In: Postgraduate Medicine, A Special Report on Clinical Experience with Losartan, the first A-II blocker, in diverse hypertensive populations. Healthcare Information Programs, McGraw-Hill Healthcare Information Group. Minneapolis, MN. 1997; 5&6.
  126. Kohlmann O, Cesaretti ML, Ginoza M, Tavares A, Zanella MT, Ribeiro AB, Ramos OL, Leeman SE, Gavras I, Gavras H. Role of substance P in blood pressure regulation in salt-dependent experimental hypertension. Hypertension. 1997 Jan; 29(1 Pt 2):506-9. PMID: 9039150.
    View in: PubMed
  127. Gavras I, Gavras H . Potencial cardioprotector de los inhibidores del enzima conversor de la angiotensina. Anales De Cirugia Cardiaca Y Cirugia Vascular. 1997; 3:185-189.
  128. Manolis AJ, Olympios C, Sifaki M, Handanis S, Cokkinos D, Bresnahan M, Gavras I, Gavras H. Combined sympathetic suppression and angiotensin-converting enzyme inhibition in congestive heart failure. Hypertension. 1997 Jan; 29(1 Pt 2):525-30. PMID: 9039154.
    View in: PubMed
  129. Johns C, Gavras I, Handy DE, Salomao A, Gavras H. Models of experimental hypertension in mice. Hypertension. 1996 Dec; 28(6):1064-9. PMID: 8952597.
    View in: PubMed
  130. Gavras HP, Salerno CM. The angiotensin II type 1 receptor blocker losartan in clinical practice: a review. Clin Ther. 1996 Nov-Dec; 18(6):1058-67; discussion 1057. PMID: 9001823.
    View in: PubMed
  131. Gavras I, Gavras H. What Data Are Required to Adopt New Antihypertensive Agents? Am J Ther. 1996 Aug; 3(8):604-607. PMID: 11862298.
    View in: PubMed
  132. Gavras I, Gavras H. Commentary on Kostis' report from SOLVD. Am J Hypertens. 1996 Jun; 9(6):615, 616-9. PMID: 8783788.
    View in: PubMed
  133. Gavras I, Gavras H. Cardioprotective potential of angiotensin converting enzyme inhibitors. Braz J Med Biol Res. 1996 Jun; 29(6):701-5. PMID: 9070382.
    View in: PubMed
  134. Handy DE, Gavras H. Evidence for cell-specific regulation of transcription of the rat alpha2A-adrenergic receptor gene. Hypertension. 1996 Apr; 27(4):1018-24. PMID: 8613257.
    View in: PubMed
  135. Tavares A, Handy DE, Bogdanova NN, Rosene DL, Gavras H. Localization of alpha 2A- and alpha 2B-adrenergic receptor subtypes in brain. Hypertension. 1996 Mar; 27(3 Pt 1):449-55. PMID: 8698452.
    View in: PubMed
  136. Wall BM, Huch KM, Runyan KR, Williams HH, Gavras H, Cooke CR. Effects of vasopressin V1-receptor blockade during acute and sustained hypovolemic hypotension. Am J Physiol. 1996 Feb; 270(2 Pt 2):R356-64. PMID: 8779866.
    View in: PubMed
  137. Gavras H, Gavras I. Endothelial function in cardiovascular disease: the role of bradykinin. In: Bradykinin. Sara Black, ed. Science Press Limited. London, UK. 1996; 1-58.
  138. Gavras H, Gavras I . Initiating antihypertensive therapy in the 1990s. In: ACE Inhibition & Your Practice. Ikram H, ed., English Thornton Communications, Inc. 1996; 1-6.
  139. Gavras H. Contemporary choices for the treatment of hypertension. Hellenic J Cardiol (Editorial). 1996; 37:493-499.
  140. Manolis A, Gavras I, Gavras H . Clonidine and heart failure. Hypertension (Letter to Editor). 1996; 27:1187-1188.
  141. Kohlmann O, Ginoza M, Cezaretti ML, Zanella MT, Ribeiro AB, Tavares A, Ramos OL, Leeman SE, Gavras I, Gavras H. Cardiovascular effects of a specific nonpeptide antagonist of substance P (NK-1) receptor in DOCA-salt hypertension. Hypertension. 1995 Dec; 26(6 Pt 2):1186-9. PMID: 7498993.
    View in: PubMed
  142. Manolis AJ, Olympios C, Sifaki M, Handanis S, Bresnahan M, Gavras I, Gavras H. Suppressing sympathetic activation in congestive heart failure. A new therapeutic strategy. Hypertension. 1995 Nov; 26(5):719-24. PMID: 7591009.
    View in: PubMed
  143. Gavras H, Gavras I. Modern approaches to initiating antihypertensive therapy. Cardiol Clin. 1995 Nov; 13(4):593-8. PMID: 8565022.
    View in: PubMed
  144. Haefliger JA, Bergonzelli G, Waeber G, Aubert JF, Nussberger J, Gavras H, Nicod P, Waeber B. Renin and angiotensin II receptor gene expression in kidneys of renal hypertensive rats. Hypertension. 1995 Nov; 26(5):733-7. PMID: 7591011.
    View in: PubMed
  145. Handy DE, Zanella MT, Kanemaru A, Tavares A, Flordellis C, Gavras H. A negative regulatory element in the promoter region of the rat alpha 2A-adrenergic receptor gene overlaps an SP1 consensus binding site. Biochem J. 1995 Oct 15; 311 ( Pt 2):541-7. PMID: 7487893.
    View in: PubMed
  146. Ruocco NA, Bergelson BA, Yu TK, Gavras I, Gavras H. Augmentation of coronary blood flow by ACE inhibition: role of angiotensin and bradykinin. Clin Exp Hypertens. 1995 Oct; 17(7):1059-72. PMID: 8556004.
    View in: PubMed
  147. Manolis AJ, Gavras I, Pieprzak M, Gavras H. Isradipine versus captopril in patients with essential hypertension. Clin Ther. 1995 Jul-Aug; 17(4):648-55. PMID: 8565028.
    View in: PubMed
  148. Gavras I, Manolis A, Gavras H. Effects of ACE inhibition on the heart. J Hum Hypertens. 1995 Jun; 9(6):455-8. PMID: 7473527.
    View in: PubMed
  149. Kohlman O, Neves Fde A, Ginoza M, Tavares A, Cezaretti ML, Zanella MT, Ribeiro AB, Gavras I, Gavras H. Role of bradykinin in insulin sensitivity and blood pressure regulation during hyperinsulinemia. Hypertension. 1995 May; 25(5):1003-7. PMID: 7737706.
    View in: PubMed
  150. Flordellis CS, Berguerand M, Gouache P, Barbu V, Gavras H, Handy DE, Béréziat G, Masliah J. Alpha 2 adrenergic receptor subtypes expressed in Chinese hamster ovary cells activate differentially mitogen-activated protein kinase by a p21ras independent pathway. J Biol Chem. 1995 Feb 24; 270(8):3491-4. PMID: 7876081.
    View in: PubMed
  151. Gavras I, Gavras H. Role of Vasopressin in Hypertensive Disorders. In: Hypertension: Pathophysiology, Diagnosis, and Management, Second Edition. Laragh JH, Brenner BM, eds. Raven Press, Ltd. New York,NY. 1995; 789-800.
  152. Huch KM, Runyan KR, Wall BM, Gavras H, Cooke CR. Hemodynamic response to vasopressin during V1-receptor antagonism in baroreflex-deficient subjects. Am J Physiol. 1995 Jan; 268(1 Pt 2):R156-63. PMID: 7840317.
    View in: PubMed
  153. Gavras H, Handy D, Gavras I. Alpha-adrenergic receptors in hypertension. In: Hypertension: Pathophysiology, Diagnosis, and Management, Second Edition. Laragh JH, Brenner BM, eds. Raven Press, Ltd. New York,NY. 1995; 853-861.
  154. Gavras H . What to anticipate from Ang II antagonists in the treatment of hypertension and chronic heart failure. High Blood Pressure Research Council Newsletter. 1995; 3:20-21.
  155. Gavras I, Gavras H . Bradykinin in hypertension and heart disease: effects of ACE inhibition. In: ACE Report 116. Nicholls MG, ed. Current Science, Ltd. 1995; 1-5.
  156. Tobian L, Brunner HR, Cohn JN, Gavras H, Laragh JH, Materson BJ, Weber MA. Modern strategies to prevent coronary sequelae and stroke in hypertensive patients differ from the JNC V Consensus Guidelines. Am J Hypertens. 1994 Oct; 7(10 Pt 1):859-72. PMID: 7826548.
    View in: PubMed
  157. Gavras H. Corcoran Lecture. Angiotensin-converting enzyme inhibition and the heart. Hypertension. 1994 Jun; 23(6 Pt 2):813-8. PMID: 8206609.
    View in: PubMed
  158. Bursztyn M, Gavras I, Gourley L, DeSilva J, Whalen J, Gavras H. Effect of combination therapy with atenolol and the angiotensin-converting enzyme inhibitor benazepril. Clin Ther. 1994 May-Jun; 16(3):429-36. PMID: 7923309.
    View in: PubMed
  159. Gavras H, Gavras I. On the JNC V report. A different point of view. Am J Hypertens. 1994 Mar; 7(3):288-93. PMID: 8003283.
    View in: PubMed
  160. Franco R, Gut A, Ferrari-Spadotto A, Georgette J, Gavras I, Gavras H. Pressor mechanisms in adriamycin-induced nephropathy with hypertension in rats. Hypertension. 1994 Jan; 23(1 Suppl):I246-9. PMID: 8282368.
    View in: PubMed
  161. de Paula RB, Plavnik FL, Rodrigues CI, Neves Fde A, Kohlmann O, Ribeiro AB, Gavras I, Gavras H. Contribution of vasopressin to orthostatic blood pressure maintenance in essential hypertension. Am J Hypertens. 1993 Sep; 6(9):794-8. PMID: 8110434.
    View in: PubMed
  162. De Paula RB, Plavnik FL, Rodrigues CI, Neves Fde A, Kohlmann Júnior O, Ribeiro AB, Gavras I, Gavras H. Age and race determine vasopressin participation in upright blood pressure control in essential hypertension. Ann N Y Acad Sci. 1993 Jul 22; 689:534-6. PMID: 8373040.
    View in: PubMed
  163. Gavras I, Gavras H. ACE inhibitors: a decade of clinical experience. Hosp Pract (Off Ed). 1993 Jul 15; 28(7):117-20, 123, 126-7. PMID: 8325908.
    View in: PubMed
  164. Handy DE, Flordellis CS, Bogdanova NN, Bresnahan MR, Gavras H. Diverse tissue expression of rat alpha 2-adrenergic receptor genes. Hypertension. 1993 Jun; 21(6 Pt 1):861-5. PMID: 7684725.
    View in: PubMed
  165. Manolis A, Athanasopoulos G, Karatasakis G, Gavras I, Bresnahan M, Cokkinos DV, Gavras H. Pressor hormone profile during stress in hypertension: does vasopressin interfere with left ventricular hypertrophy? Clin Exp Hypertens. 1993 May; 15(3):539-55. PMID: 8490595.
    View in: PubMed
  166. Sambhi MP, Gavras H, Robertson JI, Smith WM. Long-range safety and protective benefits of angiotensin-converting enzyme inhibitors for hypertension. Do we need more clinical trials? West J Med. 1993 Mar; 158(3):286-94. PMID: 8460511.
    View in: PubMed
  167. Gavras H. ACE inhibitors and myocardial infarction. Lancet. 1993 Feb 20; 341(8843):493-4. PMID: 8094511.
    View in: PubMed
  168. Gavras I, Gavras H. Angiotensin II -- Possible adverse effects on arteries, heart, brain, and kidney: Experimental, clinical, and epidemiological evidence. In: The Renin-Angiotensin System, Biochemistry Physiology Vol 1, Robertson JIS, Nicholls MG, eds. Gower Medical Publishing. London,UK. 1993; 1:40.1-40.11.
  169. Bakris GL, Gavras H. Renin in acute and chronic renal failure: implications for treatment. In: The Renin-Angiotensin System, Pathophysiology Therapeutics, Robertson JIS, Nicholls MG, eds. Gower Medical Publishing. London,UK. 1993; 2:56.1-56.14.
  170. Gavras H, Gavras I. Hypertension in the elderly: Pathophysiology of aging of the cardiovascular system. In: Nephrology and Urology in the Aged patient. Oreopoulos DG, Michelis MF, Herschorn S, eds. Kluwer Academic Publishers. 1993; 141-145.
  171. Gavras I, Gavras H. Does bradykinin contribute to the actions of angiotensin converting enzyme inhibitors?. In: Ace Report 95, Nicholls MG, ed. Current Science Ltd. 1993; 1-8.
  172. Handy DE, Gavras H. Promoter region of the human alpha 2A adrenergic receptor gene. J Biol Chem. 1992 Nov 25; 267(33):24017-22. PMID: 1385431.
    View in: PubMed
  173. Gavras H. Oral milrinone in severe chronic heart failure. N Engl J Med. 1992 Jun 4; 326(23):1566; author reply 1567. PMID: 1579143.
    View in: PubMed
  174. Wang YX, Gavras I, Wierzba T, Gavras H. Comparison of systemic and regional hemodynamic effects of a diuretic, an angiotensin II receptor antagonist, and an angiotensin-converting enzyme inhibitor in conscious renovascular hypertensive rats. J Lab Clin Med. 1992 Mar; 119(3):267-72. PMID: 1541876.
    View in: PubMed
  175. Lammek B, Konieczna E, Wierzba T, Wang YX, Gavras H. Synthesis and some pharmacological properties of new V1/V2 antagonists of arginine-vasopressin with structural changes at their N-terminals. Pol J Pharmacol Pharm. 1992 Mar-Apr; 44(2):179-86. PMID: 1409118.
    View in: PubMed
  176. Wang YX, Gavras I, Wierzba T, Lammek B, Gavras H. Inhibition of nitric oxide, bradykinin, and prostaglandins in normal rats. Hypertension. 1992 Feb; 19(2 Suppl):II255-61. PMID: 1735588.
    View in: PubMed
  177. Gavras H, Gavras I. How ACE inhibition lowers blood pressure. Choices in Cardiol 6 (suppl 1). 1992; 15-17.
  178. Gavras H, Gavras I. Hypertension in the elderly: Choosing the right therapy. J Crit Illness. 1992; 7:1862-1874.
  179. Gavras H. Early experience with quinapril in the management of hypertension. Cardiovasc Rev & Rep. 1992; 13:55-57.
  180. Lammek B, Ito Y, Gavras I, Gavras H . Acylation of the N-terminus of B2 bradykinin antagonists with bulky substituents dramatically increases potency. Collect Czech Chem Commun. 1992; 57:1960-1966.
  181. Gavras H. The role of angiotensin converting enzyme inhibitors in the management of urgent hypertensive situations: A review. Cardiovas Drug Rev. 1992; 10:117-124.
  182. Lammek B, Wang YX, Gavras I, Gavras H. A novel bradykinin antagonist with improved properties. J Pharm Pharmacol. 1991 Dec; 43(12):887-8. PMID: 1687595.
    View in: PubMed
  183. Castellano M, Handy DE, Beschi M, Wang YX, Agabiti-Rosei E, Gavras H. Gene expression of catecholaminergic receptors in the central nervous system of hypertensive rats. J Hypertens Suppl. 1991 Dec; 9(6):S54-5. PMID: 1819011.
    View in: PubMed
  184. Gavras H, Gavras I. Angiotensin converting enzyme inhibitors. J Hypertens. 1991 Nov; 9(11):1075-6. PMID: 1661767.
    View in: PubMed
  185. Gavras H. Role of vasopressin in clinical hypertension and congestive cardiac failure: interaction with the sympathetic nervous system. Clin Chem. 1991 Oct; 37(10 Pt 2):1828-30. PMID: 1914197.
    View in: PubMed
  186. Wang YX, Gavras I, Lammek B, Bresnahan M, Gavras H. Effects of bradykinin and prostaglandin inhibition on systemic and regional hemodynamics in conscious normotensive rats. J Hypertens. 1991 Sep; 9(9):805-12. PMID: 1663981.
    View in: PubMed
  187. Gavras I, Gavras H. Cardioprotective potential of angiotensin-converting enzyme inhibitors. Clin Cardiol. 1991 Aug; 14(8 Suppl 4):IV68-71; discussion IV83-90. PMID: 1893645.
    View in: PubMed
  188. Gavras H, Gavras I. Cardioprotective potential of angiotensin converting enzyme inhibitors. J Hypertens. 1991 May; 9(5):385-92. PMID: 1649858.
    View in: PubMed
  189. Wang YX, Franco R, Gavras I, Gavras H. Effects of chronic administration of a vasopressin antagonist with combined antivasopressor and antiantidiuretic activities in rats with left ventricular dysfunction. J Lab Clin Med. 1991 Apr; 117(4):313-8. PMID: 1826304.
    View in: PubMed
  190. Flordellis CS, Handy DE, Bresnahan MR, Zannis VI, Gavras H. Cloning and expression of a rat brain alpha 2B-adrenergic receptor. Proc Natl Acad Sci U S A. 1991 Feb 1; 88(3):1019-23. PMID: 1704126.
    View in: PubMed
  191. Bursztyn M, Gavras H. Clinical aspects of oral angiotensin converting enzyme inhibitors. In: Progress in Hypertension. Saito H, Minami M, Parvez SH, eds. VSP BV. The Netherlands. 1991; 2:107-129.
  192. Bakris GL, Gavras H . Treatment of hypertension in the elderly: a review: Geriatr Nephrol & Urol. 1991; 1:121-127.
  193. Gavras H, Gavras I . Effects of bradykinin antagonists on the cardiovascular system. In: Bradykinin Antagonists Basic & Clinical Research. Burch RM, ed. Marcel Dekker. New York,NY. 1991; 171-189.
  194. Lammek B, Wang YX, Franco R, Gavras I, Gavras H. Two highly effective V1/V2 antagonists of vasopressin containing novel thioacids at position 1. J Pharm Pharmacol. 1991 Jan; 43(1):40-2. PMID: 1676057.
    View in: PubMed
  195. Lammek B, Wang Y-X, Gavras H . Synthesis and some pharmacologic properties of three new bradykinin antagonists. Coll Czech Chem Comm. 1991; 56:1539-1544.
  196. Gavras H. Angiotensin-converting enzyme inhibitors in hypertension and congestive heart failure. J KAU: Med Sci (1411 A.H./1991 A.D.). 1991; 1:3-8.
  197. Gavras H. Pressor systems in hypertension and congestive heart failure. Role of vasopressin. Hypertension. 1990 Nov; 16(5):587-93. PMID: 2228158.
    View in: PubMed
  198. Lammek B, Wang YX, Gavras I, Gavras H. A new highly potent antagonist of bradykinin. Peptides. 1990 Nov-Dec; 11(6):1319. PMID: 2087444.
    View in: PubMed
  199. Lammek B, Wang YX, Gavras I, Gavras H. A new highly potent antagonist of bradykinin. Peptides. 1990 Sep-Oct; 11(5):1041-3. PMID: 2284196.
    View in: PubMed
  200. Gavras H. [International experience with the use of lisinopril in arterial hypertension]. Arq Bras Cardiol. 1990 Aug; 55 Suppl A:A20-2. PMID: 1965523.
    View in: PubMed
  201. Bursztyn M, Bresnahan M, Gavras I, Gavras H. Effect of aging on vasopressin, catecholamines, and alpha 2-adrenergic receptors. J Am Geriatr Soc. 1990 Jun; 38(6):628-32. PMID: 2162869.
    View in: PubMed
  202. Flordellis CS, Castellano M, Franco R, Zannis VI, Gavras H. Expression of multiple alpha 2-adrenergic receptor messenger RNA species in rat tissues. Hypertension. 1990 Jun; 15(6 Pt 2):881-7. PMID: 2161794.
    View in: PubMed
  203. Bresnahan MR, Flordellis CS, Vassilatis DK, Makrides SC, Zannis VI, Gavras H. High level of expression of functional human platelet alpha 2-adrenergic receptors in a stable mouse C127 cell line. Biochim Biophys Acta. 1990 May 22; 1052(3):439-45. PMID: 1972337.
    View in: PubMed
  204. Bursztyn M, Gavras I, Tifft CP, Luther R, Boger R, Gavras H. Effects of a novel renin inhibitor in patients with essential hypertension. J Cardiovasc Pharmacol. 1990 Mar; 15(3):493-500. PMID: 1691375.
    View in: PubMed
  205. Bursztyn M, Bresnahan M, Gavras I, Gavras H. Pressor hormones in elderly hypertensive persons. Racial differences. Hypertension. 1990 Feb; 15(2 Suppl):I88-92. PMID: 2153631.
    View in: PubMed
  206. Mulinari RA, Gavras I, Wang YX, Franco R, Gavras H. Effects of a vasopressin antagonist with combined antipressor and antiantidiuretic activities in rats with left ventricular dysfunction. Circulation. 1990 Jan; 81(1):308-11. PMID: 2404626.
    View in: PubMed
  207. Gavras I, Gavras H. Angiotensin-converting enzyme inhibitors in hypertension and congestive heart failure. Adv Intern Med. 1990; 35:249-67. PMID: 2405595.
    View in: PubMed
  208. Gavras I, Gavras H . Enalapril. In: Cardiovascular Drug Therapy. Messerli F, ed. WB Saunders Co. Philadelphia, PA. 1990; 792-799.
  209. Gavras I, Gavras H. The future of converting enzyme inhibitors as cardioprotective agents. Curr Opin in Cardiol. 1990; 5:626-629.
  210. Chobanian AV, Gavras H. Hypertension. Clin Symp. 1990; 42(5):1-32. PMID: 2276260.
    View in: PubMed
  211. Wang YX, Franco R, Gavras I, Gavras H . Effects of chronic administration of a vasopressin antagonist with combined antivasopressor and anti-antidiuretic activities in rats with left ventricular dysfunction. Clin Res. 1990; 38:583A.
  212. Gavras I, Gavras H. Enalapril. In: Drugs for the Heart and Circulation. Messerli FH, ed. WB Saunders Co. 1990; 792-799.
  213. Gavras H . Angiotensin-Converting Enzyme Inhibitors or Calcium Channel Blockers? An Overview. Drugs 39 (Suppl 2). 1990; 73-75.
  214. Gavras H. Angiotensin converting enzyme inhibition and its impact on cardiovascular disease. Circulation. 1990 Jan; 81(1):381-8. PMID: 2404627.
    View in: PubMed
  215. Gavras I, Gavras H. Angiotensin-converting enzyme inhibitors in hypertension and congestive heart failure. In: Adv Intern Med. Year Book Medical Publishers, Inc. 1990; 35:249-267.
  216. Wierzba T, Manolis A, Gavras I, Bursztyn M, Gavras H. Enalapril in mild to moderate hypertension. Curr Ther Res. 1990; 48(6):1101-1110.
  217. Waeber B, Niederberger M, Gavras H, Nussberger J, Brunner HR. Hemodynamic effects of a kinin antagonist. J Cardiovasc Pharmacol. 1990; 15 Suppl 6:S78-82. PMID: 1697367.
    View in: PubMed
  218. Bursztyn M, Gavras I, Tifft CP, Bauer JH, Melby JC, Gavras H. Renin inhibition with A-64662: effect on blood pressure and hormonal response in man. J Hypertens Suppl. 1989 Dec; 7(6):S306-7. PMID: 2698944.
    View in: PubMed
  219. Wallin JD, Cook ME, Fletcher E, Holtzman JL, Winer N, Gavras H, Grim CE, Ramanathan KB, Vidt DG, Johnson BF, et al. Dilevalol in severe hypertension. A multicenter trial of bolus intravenous dosing. Arch Intern Med. 1989 Dec; 149(12):2655-61. PMID: 2688585.
    View in: PubMed
  220. Lammek B, Wang YX, Derdowska I, Franco R, Gavras H. Synthesis and some pharmacologic properties of five novel V1 or V1/V2 antagonists of AVP. Peptides. 1989 Sep-Oct; 10(5):1109-12. PMID: 2608555.
    View in: PubMed
  221. Gavras H, Gavras I. Salt-induced hypertension: the interactive role of vasopressin and of the sympathetic nervous system. J Hypertens. 1989 Aug; 7(8):601-6. PMID: 2681406.
    View in: PubMed
  222. Bursztyn M, Gavras I, Gavras H. Hypertension in the aging patient. Implications for the selection of drug therapy. J Am Geriatr Soc. 1989 Aug; 37(8):814-8. PMID: 2754162.
    View in: PubMed
  223. Glazier JJ, Faxon DP, Mills RM, Bresnahan MR, Ryan TJ, Gavras H. Effect of arginine vasopressin on coronary and systemic hemodynamics in man. Int J Cardiol. 1989 Jul; 24(1):95-103. PMID: 2759761.
    View in: PubMed
  224. Mulinari R, Gavras I, Franco R, Gavras H. Bradykinin antagonism and prostaglandins in blood pressure regulation. Hypertension. 1989 Jun; 13(6 Pt 2):960-3. PMID: 2567708.
    View in: PubMed
  225. Bursztyn M, Gavras I, Blasucci DJ, Gavras H. Intravenous dilevalol in the treatment of severe hypertension. J Cardiovasc Pharmacol. 1989 May; 13(5):799-802. PMID: 2472530.
    View in: PubMed
  226. Gavras I, Gavras H. Role of vasopressin in hypertensive disorders. In: Hypertension: Pathophysiology, Diagnosis and Management. Laragh JH and Brenner BM, eds. Raven Press. New York,NY. 1989; 779-789.
  227. Gavras H . Cardioprotective effects of angiotensin-converting-enzyme inhibitors in hypertension. Practical Cardiology. 1989; 15:25-31.
  228. Glazier JJ, Gavras H, Mills RM, Bresnahan M, Ryan TJ, Faxon DP. What is the effect of arginine vasopressin on coronary and systemic vascular tone in man?. Clin Sci. 1989; 77(Suppl 21):34P.
  229. Mulinari R, Gavras I, Gavras H. The role of vasopressin in blood pressure regulation. In: Perspectives in Hypertension: II Endocrine mechanisms of Hypertension. Brenner BM, Kaplan N, Laragh JH, eds. Raven Press. New York,NY. 1989; 201-218.
  230. Flordellis C, Castellano M, Zannis V, Gavras H. Tissue-specific expression of alpha2-adrenoceptor mRNA isoforms in rat. Hypertension. 1989; 14:353.
  231. Bursztyn M, Gavras I, Gavras H. Quinapril: Mechanism of action, safety, and effectiveness. Inter Med. 1989; 10:79-85.
  232. Gavras H. The place of angiotensin-converting enzyme inhibition in the treatment of cardiovascular diseases. N Engl J Med. 1988 Dec 8; 319(23):1541-3. PMID: 3185679.
    View in: PubMed
  233. Gavras I, Mulinari R, Gavras H. Renin-angiotensin and vasopressin in the development of salt-induced hypertension. J Hypertens. 1988 Dec; 6(12):999-1002. PMID: 2975694.
    View in: PubMed
  234. Gavras H. Effect of sodium on central alpha 2-adrenergic receptors. Hypertension. 1988 Nov; 12(5):525-6. PMID: 2847984.
    View in: PubMed
  235. Vlahakos D, Gavras H. Central sympathetic stimulation produced by saline application into the nucleus tractus solitarii area of conscious rats. Neurosci Lett. 1988 Oct 17; 92(3):335-40. PMID: 3200489.
    View in: PubMed
  236. Makrides SC, Mulinari R, Zannis VI, Gavras H. Regulation of renin gene expression in hypertensive rats. Hypertension. 1988 Oct; 12(4):405-10. PMID: 3049341.
    View in: PubMed
  237. Gavras I, Gavras H. Anti-hormones and blood pressure: bradykinin antagonists in blood pressure regulation. Kidney Int Suppl. 1988 Oct; 26:S60-2. PMID: 3059034.
    View in: PubMed
  238. Paglin S, Takuwa Y, Kamm KE, Stull JT, Gavras H, Rasmussen H. Atrial natriuretic peptide inhibits the agonist-induced increase in extent of myosin light chain phosphorylation in aortic smooth muscle. J Biol Chem. 1988 Sep 15; 263(26):13117-20. PMID: 2971037.
    View in: PubMed
  239. Mulinari RA, Gouni I, Gavras I, Gavras H. Acute effects of the new angiotensin-converting enzyme inhibitor cilazapril: a pilot study. J Clin Pharmacol. 1988 Jul; 28(7):660-3. PMID: 2975290.
    View in: PubMed
  240. Mulinari R, Benetos A, Gavras I, Gavras H. Vascular and sympathoadrenal responses to bradykinin and a bradykinin analogue. Hypertension. 1988 Jun; 11(6 Pt 2):754-7. PMID: 2899059.
    View in: PubMed
  241. Gavras I, Gavras H. Role of bradykinin in hypertension and the antihypertensive effect of angiotensin-converting enzyme inhibitors. Am J Med Sci. 1988 Apr; 295(4):305-7. PMID: 2834950.
    View in: PubMed
  242. Gavras H, Gavras I. Angiotensin converting enzyme inhibitors. Properties and side effects. Hypertension. 1988 Mar; 11(3 Pt 2):II37-41. PMID: 3280490.
    View in: PubMed
  243. Saad CI, Ribeiro AB, Zanella MT, Mulinari RA, Gavras I, Gavras H. The role of vasopressin in blood pressure maintenance in diabetic orthostatic hypotension. Hypertension. 1988 Feb; 11(2 Pt 2):I217-21. PMID: 3346060.
    View in: PubMed
  244. Gavras I, Bursztyn M, Gavras H . Changing trends in hypertension therapy: ACE inhibitors and calcium blockers. Mod Medicine. 1988; 56:106-117.
  245. Gavras I, Mulinari R, Ribeiro A, Gavras H . Role of vasopressin in hypertension and heart failure: Clinical Studies. In: Vasopressin : Cellular and Integrative Functions. Cowley AW, ed. Raven Press. New York,NY. 1988; 467-479.
  246. Gavras I, Mulinari R, Gavras H, Higgins JT, Reeves RL, Zawada ET, Crook J, Halperin AK, Garrett B. Antihypertensive effectiveness of the nifedipine gastrointestinal therapeutic system. Am J Med. 1987 Dec 21; 83(6B):20-3. PMID: 3332575.
    View in: PubMed
  247. Schneider SH, Khachadurian AK, Amorosa LF, Gavras H, Fineberg SE, Ruderman NB. Abnormal glucoregulation during exercise in type II (non-insulin-dependent) diabetes. Metabolism. 1987 Dec; 36(12):1161-6. PMID: 3316925.
    View in: PubMed
  248. Benetos A, Bresnahan M, Gavras I, Gavras H. Central catecholamines and alpha-adrenoceptors in acute hypertension induced by intracerebroventricular hypertonic saline. J Hypertens. 1987 Dec; 5(6):699-704. PMID: 2828469.
    View in: PubMed
  249. Gavras H, Benetos A, Gavras I. Contribution of bradykinin to maintenance of normal blood pressure. Hypertension. 1987 Jun; 9(6 Pt 2):III147-9. PMID: 3596781.
    View in: PubMed
  250. Benetos A, Gavras I, Gavras H. Stimulation of vasopressin by calcium microinjections in the area of the paraventricular nucleus of the hypothalamus. Brain Res. 1987 May 26; 412(1):182-4. PMID: 3607454.
    View in: PubMed
  251. Gavras I, Gavras H. [Clinical management of hypertension in the elderly]. Rev Clin Esp. 1987 Mar; 180(5):229-31. PMID: 3602521.
    View in: PubMed
  252. Papadoliopoulou-Diamandopoulou N, Papagalanis N, Gavras I, Gavras H. Vasopressin in end-stage renal disease: relationship to salt, catecholamines and renin activity. Clin Exp Hypertens A. 1987; 9(7):1197-208. PMID: 3304733.
    View in: PubMed
  253. Gavras I, Gavras H. Clinical management of hypertension in the elderly. In: Hypertension in the Community, Eds Rosenthal T, Silderberg D. Karger Publ. 1987; 62-67.
  254. Gavras I, Gavras H. The role of angiotensin converting enzyme inhibitors in hypertension. In: The pharmacological treatment of cardiovascular diseases. Kostis JB, DeFelice EA, eds. MEPC. Alan Liss Inc. New York,NY. 1987; 93-122.
  255. Benetos A, Gavras H, Stewart JM, Vavrek R, Hatinoglou S, Gavras I. The antihypertensive contribution of bradykinin as assessed by a specific bradykinin antagonist. Agents Actions Suppl. 1987; 22:355-64. PMID: 2829598.
    View in: PubMed
  256. Mulinari R, Gavras I, Gavras H. Efficacy and tolerability of enalapril monotherapy in mild-to-moderate hypertension in older patients compared to younger patients. Clin Ther. 1987; 9(6):678-89. PMID: 2830974.
    View in: PubMed
  257. Bresnahan MR, Gavras I, Hatinoglou S, Muller RE, Gavras H. Central alpha-adrenoceptors during the development of hypertension in rats on high and low salt intake. J Hypertens. 1986 Dec; 4(6):719-26. PMID: 3029217.
    View in: PubMed
  258. Young JC, Treadway JL, Balon TW, Gavras HP, Ruderman NB. Prior exercise potentiates the thermic effect of a carbohydrate load. Metabolism. 1986 Nov; 35(11):1048-53. PMID: 3534517.
    View in: PubMed
  259. Benetos A, Gavras H, Stewart JM, Vavrek RJ, Hatinoglou S, Gavras I. Vasodepressor role of endogenous bradykinin assessed by a bradykinin antagonist. Hypertension. 1986 Nov; 8(11):971-4. PMID: 3021624.
    View in: PubMed
  260. Benetos A, Gavras I, Gavras H. Hypertensive effect of a bradykinin antagonist in normotensive rats. Hypertension. 1986 Nov; 8(11):1089-92. PMID: 3770870.
    View in: PubMed
  261. Gavras I, Gavras H. Clinical utility of angiotensin converting enzyme inhibitors in hypertension. Am J Med. 1986 Oct 31; 81(4C):28-31. PMID: 3022582.
    View in: PubMed
  262. Benetos A, Gavras I, Gavras H. Norepinephrine applied in the paraventricular hypothalamic nucleus stimulates vasopressin release. Brain Res. 1986 Sep 3; 381(2):322-6. PMID: 3827993.
    View in: PubMed
  263. Gavras I, Hatinoglou S, Benetos A, Gavras H. Calcium stimulates vasopressin release. J Hypertens. 1986 Aug; 4(4):451-4. PMID: 3772099.
    View in: PubMed
  264. Gavras I, Hatinoglou S, Gavras H. The adrenergic system and the release and pressor action of vasopressin. Hypertension. 1986 Jun; 8(6 Pt 2):II163-7. PMID: 2873100.
    View in: PubMed
  265. Creager MA, Faxon DP, Cutler SS, Kohlmann O, Ryan TJ, Gavras H. Contribution of vasopressin to vasoconstriction in patients with congestive heart failure: comparison with the renin-angiotensin system and the sympathetic nervous system. J Am Coll Cardiol. 1986 Apr; 7(4):758-65. PMID: 3514728.
    View in: PubMed
  266. Ribeiro A, Mulinari R, Gavras I, Kohlmann O Jr, RAMOS O, Gavras H: . Sequential elimination of pressor mechanisms in severe hypertension in humans. Hypertension. 1986; 8(Suppl I):I-169-I-173.
  267. Gavras H. A multicenter trial of enalapril in the treatment of essential hypertension. Clin Ther. 1986; 9(1):24-38. PMID: 3028633.
    View in: PubMed
  268. Strauss R, Gavras I, Vlahakos D, Gavras H. Enalaprilat in hypertensive emergencies. J Clin Pharmacol. 1986 Jan; 26(1):39-43. PMID: 3005376.
    View in: PubMed
  269. Gavras H. How does salt raise blood pressure? A hypothesis. Hypertension. 1986 Jan; 8(1):83-8. PMID: 3002978.
    View in: PubMed
  270. Gavras H, Gavras I. Inhibitors of the renin-angiotensin system. In: Tratado Sobre Hipertension Arterial. Rodicio JL, et Madrid. 1986.
  271. Vlahakos D, Gavras I, Gavras H. alpha-Adrenoceptor agonists applied in the area of the nucleus tractus solitarii in the rat: effect of anesthesia on cardiovascular responses. Brain Res. 1985 Nov 18; 347(2):372-5. PMID: 2866015.
    View in: PubMed
  272. Gavras H, Bain GT, Bland L, Vlahakos D, Gavras I. Hypertensive response to saline microinjection in the area of the nucleus tractus solitarii of the rat. Brain Res. 1985 Sep 16; 343(1):113-9. PMID: 2994826.
    View in: PubMed
  273. Fahmy NR, Gavras HP. Impact of captopril on hemodynamic and hormonal effects of nitroprusside. J Cardiovasc Pharmacol. 1985 Sep-Oct; 7(5):869-74. PMID: 2413294.
    View in: PubMed
  274. Gavras I, Gavras H. Nifedipine in the treatment of essential hypertension. J Clin Pharmacol. 1985 Sep; 25(6):429-32. PMID: 3902911.
    View in: PubMed
  275. Chatterjee K, Parmley WW, Cohn JN, Levine TB, Awan NA, Mason DT, Faxon DP, Creager M, Gavras HP, Fouad FM, et al. A cooperative multicenter study of captopril in congestive heart failure: hemodynamic effects and long-term response. Am Heart J. 1985 Aug; 110(2):439-47. PMID: 3895877.
    View in: PubMed
  276. Creager MA, Faxon DP, Rockwell SM, Gavras H, Coffman JD. The contribution of the renin-angiotensin system to limb vasoregulation in patients with heart failure: observations during orthostasis and alpha-adrenergic blockade. Clin Sci (Lond). 1985 Jun; 68(6):659-67. PMID: 2485267.
    View in: PubMed
  277. Kohlmann O, Gavras I, Biollaz J, Biollaz B, Gavras H. Sodium chloride-induced partial inhibition in vivo of alpha 2-adrenoceptor agonist function. J Hypertens. 1985 Jun; 3(3):269-74. PMID: 2862207.
    View in: PubMed
  278. Gavras H, Gavras I. Managing hypertensives with parenchymal renal disease. Cardiovasc Med. 1985; 10(2):43-54.
  279. Charocopos F, Gavras H. Cardiovascular effects of dobutamine and converting enzyme inhibition in rats with diabetic ketoacidosis. Pharmacology. 1985; 30(2):65-70. PMID: 2983358.
    View in: PubMed
  280. Gavras H, Gavras I. Risk of stroke in the hypertensive elderly patient. Geriatric Med Today. 1985; 4(11):72-75.
  281. Gavras H, Gavras I. Interaction of vasopressin with the sympathetic nervous system and arterial pressure and control. In: Vasopressin, Robert W Schrier, ed. Raven Press. New York,NY. 1985.
  282. Madias JE, Madias NE, Gavras HP. Nonarrhythmogenicity of diuretic-induced hypokalemia. Its evidence in patients with uncomplicated hypertension. Arch Intern Med. 1984 Nov; 144(11):2171-6. PMID: 6497518.
    View in: PubMed
  283. Ying CY, Tifft CP, Gavras H, Chobanian AV. Renal revascularization in the azotemic hypertensive patient resistant to therapy. N Engl J Med. 1984 Oct 25; 311(17):1070-5. PMID: 6237260.
    View in: PubMed
  284. Gavras I, Vlahakos D, Melby JC, Gavras H. Pilot study of the effects of the angiotensin-converting enzyme inhibitor CI-906 on patients with essential hypertension. J Clin Pharmacol. 1984 Aug-Sep; 24(8-9):343-50. PMID: 6090509.
    View in: PubMed
  285. Biollaz B, Biollaz J, Kohlman O, Bresnahan M, Gavras I, Gavras H. Acute cardiovascular effects of two central phenylethanolamine-N-methyl-transferase inhibitors in unanesthetized desoxycorticosterone-salt hypertensive rats. Eur J Pharmacol. 1984 Jul 20; 102(3-4):515-9. PMID: 6489438.
    View in: PubMed
  286. Charocopos F, Gavras H. Cardiovascular responses in the diabetic rat. Q J Exp Physiol. 1984 Jul; 69(3):463-8. PMID: 6236471.
    View in: PubMed
  287. Hatzinikolaou P, Gavras H, North WG, Kohlmann O, Gavras I. Evidence for dopaminergic regulation of vasopressin release in the anephric rat. J Hypertens. 1984 Jun; 2(3):311-5. PMID: 6442313.
    View in: PubMed
  288. Kohlmann O, Bresnahan M, Gavras H. Central and peripheral indices of sympathetic activity after blood pressure lowering with enalapril (MK-421) or hydralazine in normotensive rats. Hypertension. 1984 Mar-Apr; 6(2 Pt 2):I1-6. PMID: 6327520.
    View in: PubMed
  289. Gavras H, Ribeiro AB, Kohlmann O, Saragoça M, Mulinari RA, Ramos O, Gavras I. Effects of a specific inhibitor of the vascular action of vasopressin in humans. Hypertension. 1984 Mar-Apr; 6(2 Pt 2):I156-60. PMID: 6547112.
    View in: PubMed
  290. Creager MA, Faxon DP, Rockwell SM, Melby JC, Gavras H, Coffman JD. Effect of renin-angiotensin system on limb circulation in normal subjects. Am J Physiol. 1984 Feb; 246(2 Pt 2):H239-44. PMID: 6364845.
    View in: PubMed
  291. Charocopos F, Hatzinikolaou P, Gavras I, Gavras H. Regional blood flows and cardiac hemodynamics in renovascular and mineralocorticoid hypertensive rats. J Physiol (Paris). 1984; 79(3):162-5. PMID: 6381695.
    View in: PubMed
  292. DiPette D, Gavras I, North W, DiPette P, Gavras H. Vasopressin response to hyperosmotic stimulus: blood pressure effect in normal subjects and patients with impaired sympathetic system. Clin Exp Hypertens A. 1984; 6(4):851-61. PMID: 6723091.
    View in: PubMed
  293. Bussien JP, Waeber B, Nussberger J, Schaller MD, Gavras H, Hofbauer K, Brunner HR. Does vasopressin sustain blood pressure of normally hydrated healthy volunteers? Am J Physiol. 1984 Jan; 246(1 Pt 2):H143-7. PMID: 6364837.
    View in: PubMed
  294. Waeber B, Gavras H, Bresnahan MR, Gavras I, Brunner HR. Role of vasoconstrictor systems in experimental glucocorticoid-hypertension in rats. Clin Sci (Lond). 1983 Sep; 65(3):255-61. PMID: 6872460.
    View in: PubMed
  295. Gavras I, Gavras H. Captopril and enalapril. Ann Intern Med. 1983 Apr; 98(4):556-7. PMID: 6301322.
    View in: PubMed
  296. DiPette D, Waeber B, Volicer L, Chao P, Gavras I, Gavras H, Brunner H. Salt-induced hypertension in chronic renal failure: evidence for a neurogenic mechanism. Life Sci. 1983 Feb 14; 32(7):733-40. PMID: 6827908.
    View in: PubMed
  297. Gavras H. Hypertension and congestive heart failure: benefits of converting enzyme inhibition (captopril). J Am Coll Cardiol. 1983 Feb; 1(2 Pt 1):518-20. PMID: 6338084.
    View in: PubMed
  298. Hatzinikolaou P, Charocopos F, Gavras I, Gavras H. Systemic and regional hemodynamic effects of propranolol in intact and anephric rats. Clin Exp Hypertens A. 1983; 5(5):729-39. PMID: 6883742.
    View in: PubMed
  299. Burnier M, Biollaz J, Brunner DB, Gavras H, Brunner HR. Alpha and beta adrenoceptor blockade in normotensive and deoxycorticosterone (DOC)-hypertensive rats; plasma vasopressin and vasopressin pressor effect. J Pharmacol Exp Ther. 1983 Jan; 224(1):222-7. PMID: 6129318.
    View in: PubMed
  300. Gavras H, Gavras I. Hypertension in the elderly. John Wright PS Inc. Boston,MA. 1983.
  301. Gavras I, Gavras H . Captopril and enalapril. Ann Int Med (Reply to letter). 1983; 99:281.
  302. Chobanian AV, Gavras H . Hypertensive emergencies. In: Medical emergencies diagnostic and management procedures from the Boston City Hospital, Cohen AS, Combes JR, Koh HK, eds. 2nd edition. Little Brown and Company. Boston,MA. 1983; 105-114.
  303. Gavras H, Biollaz J, Waeber B, Brunner HR, Gavras I. Clinical application of orally active angiotensin converting enzyme inhibitors. Adv Exp Med Biol. 1983; 156 (Pt B):1127-31. PMID: 6305164.
    View in: PubMed
  304. Liang CS, Gavras H, Black J, Sherman LG, Hood WB. Renin-angiotensin system inhibition in acute myocardial infarction in dogs. Effects on systemic hemodynamics, myocardial blood flow, segmental myocardial function and infarct size. Circulation. 1982 Dec; 66(6):1249-55. PMID: 6183019.
    View in: PubMed
  305. Halperin JL, Faxon DP, Creager MA, Bass TA, Melidossian CD, Gavras H, Ryan TJ. Coronary hemodynamic effects of angiotensin inhibition by captopril and teprotide in patients with congestive heart failure. Am J Cardiol. 1982 Nov; 50(5):967-72. PMID: 6182786.
    View in: PubMed
  306. Biollaz J, Brunner HR, Gavras I, Waeber B, Gavras H. Antihypertensive therapy with MK 421: angiotensin II--renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol. 1982 Nov-Dec; 4(6):966-72. PMID: 6185790.
    View in: PubMed
  307. Waeber B, Gavras H, Gavras I, Chao P, Kohlman O, Bresnahan MR, Brunner HR, Vaughan D. Evidence for a sodium-induced activation of central neurogenic mechanisms in one-kidney, one-clip renal hypertensive rats. J Pharmacol Exp Ther. 1982 Nov; 223(2):510-5. PMID: 6752375.
    View in: PubMed
  308. Charocopos F, Hatzinikolaou P, North WG, Gavras H. Systemic and regional hemodynamic effects of endogenous vasopressin stimulation in rats. Am J Physiol. 1982 Oct; 243(4):H560-5. PMID: 7124963.
    View in: PubMed
  309. Waeber B, Brunner HR, Haeusler G, Gavras H. Pre- and postsynaptic effects of SKF64139, a phenylethanolamine N-methyltransferase inhibitor, in conscious normotensive rats. J Cardiovasc Pharmacol. 1982 Sep-Oct; 4(5):759-64. PMID: 6182406.
    View in: PubMed
  310. Use of saralasin as a diagnostic test in hypertension. Report of a Consensus Committee. Arch Intern Med. 1982 Aug; 142(8):1437-40. PMID: 7049102.
    View in: PubMed
  311. Andrews P, Papadakis N, Gavras H. Reversal of experimental acute cerebral vasospasm by angiotensin converting enzyme inhibition. Stroke. 1982 Jul-Aug; 13(4):480-3. PMID: 6179264.
    View in: PubMed
  312. Liang C, Doherty JU, Faillace R, Maekawa K, Arnold S, Gavras H, Hood WB. Insulin infusion in conscious dogs. Effects on systemic and coronary hemodynamics, regional blood flows, and plasma catecholamines. J Clin Invest. 1982 Jun; 69(6):1321-36. PMID: 6123523.
    View in: PubMed
  313. Biollaz J, Dürr J, Brunner HR, Porchet M, Gavras H. Escape from mineralocorticoid excess: the role of angiotensin II. J Clin Endocrinol Metab. 1982 Jun; 54(6):1187-93. PMID: 6281293.
    View in: PubMed
  314. Gavras H, Hatzinikolaou P, North WG, Bresnahan M, Gavras I. Interaction of the sympathetic nervous system with vasopressin and renin in the maintenance of blood pressure. Hypertension. 1982 May-Jun; 4(3):400-5. PMID: 7040232.
    View in: PubMed
  315. DiPette DJ, Gavras I, North WG, Brunner HR, Gavras H. Vasopressin in salt-induced hypertension of experimental renal insufficiency. Hypertension. 1982 May-Jun; 4(3 Pt 2):125-30. PMID: 7068202.
    View in: PubMed
  316. Burnier M, Biollaz J, Brunner HR, Turini GA, Gavras H. Comparison in normal volunteers of three converting enzyme inhibitors: RHC 3659, MK 421 and captopril. Am J Cardiol. 1982 Apr 21; 49(6):1550-1. PMID: 6280484.
    View in: PubMed
  317. Waeber B, Gavras I, Brunner HR, Cook CA, Charocopos F, Gavras HP. Prediction of sustained antihypertensive efficacy of chronic captopril therapy: relationships to immediate blood pressure response and control plasma renin activity. Am Heart J. 1982 Mar; 103(3):384-90. PMID: 6278905.
    View in: PubMed
  318. Gavras I, Gavras H. Leukopenia: idiopathic or drug-induced? N Engl J Med. 1982 Feb 25; 306(8):484. PMID: 7057850.
    View in: PubMed
  319. Waeber B, Brunner HR, Burckhardt P, Gavras H. Hypertension in a patient with hypercalcemia: captopril and verapamil. Arch Intern Med. 1982 Jan; 142(1):143-5. PMID: 7032443.
    View in: PubMed
  320. Burnier M, Biollaz J, Brunner HR, Gavras H. Vasopressin blood pressure dependency following beta-adrenoceptor blockade in normotensive and mineralocorticoid-salt hypertensive rats. Ninth Scientific Meeting of the Int Soc Hypertens. 1982; 61.
  321. Gavras H, Biollaz J, Waeber B, Brunner HR, Gavras I . Clinical application of orally active angiotensin converting enzyme inhibitors. In: Mechanisms of action of antihypertensive drugs. Dollery CT, Frohlich ED, eds. Guadalajara, Mexico. 1982.
  322. Waeber B, Brunner HR, Gavras H . The renin-angiotensin system and its inhibition in the treatment of hypertension. In: Hypertension, Sleight P, Freis ED, eds. Butterworth Scientific. London,UK. 1982; 293-305.
  323. Gavras I, Gavras H, Chobanian AV, Tifft CP, Melby JC, Jick H. Hypertension and age: clinical and biochemical correlates. Clin Exp Hypertens A. 1982; 4(7):1097-106. PMID: 6749343.
    View in: PubMed
  324. Brunner HR, Waeber B, Biollaz J, Gavras H. Acute and long-term inhibition of the renin-angiotensin system. In: Mechanisms of action of antihypertensive drugs. Dollery CT, Frohlich ED, eds. Guadalajara, Mexico. 1982.
  325. Dipette D, Dipette P, North WG, Gavras I, Brunner HR, Gavras H . Plasma vasopressin response to hyperosmotic solution (renograffin) and its effect on blood pressure in quadriplegic patients. Clin Res. 1982; 30:510.
  326. Richter EA, Ruderman NB, Gavras H, Belur ER, Galbo H. Muscle glycogenolysis during exercise: dual control by epinephrine and contractions. Am J Physiol. 1982 Jan; 242(1):E25-32. PMID: 7058885.
    View in: PubMed
  327. Hatzinikolaou P, Gavras I, North WG, Brunner HR, Gavras H. Interaction of the sympathetic nervous system with vasopressin and renin in the maintenance of blood pressure in rats. Clin Sci. 1982; 63:313s-317s.
  328. Burnier M, Biollaz J, Brunner HR, Gavras H . Vasopressin blood pressure dependency after alpha-adrenoceptor blockade in normotensive and mineralocorticoid salt hypertensive rats. Clin Sci. 1982; 101s-103s.
  329. Faxon DP, Creager MA, Halperin JL, Sussman HA, Gavras H, Ryan TJ. The effect of angiotensin converting enzyme inhibition of coronary blood flow and hemodynamics in patients without coronary artery disease. Int J Cardiol. 1982; 2(2):251-62. PMID: 6185446.
    View in: PubMed
  330. Gavras H, Biollaz J, Waeber B, Brunner HR, Gavras I, Davies RO. Effects of the new oral angiotensin converting enzyme inhibitor MK-421 in human hypertension. Clin Exp Hypertens A. 1982; 4(1-2):303-14. PMID: 6280900.
    View in: PubMed
  331. Brunner HR, Gavras H. Renin and angiotensin II, aldosterone, salt and the kidney. In: Clinical Hypertension and Hypotension. Brunner HR, Gavras H, eds. Marcel Dekker Inc. New York,NY. 1982.
  332. Gavras H. Possible mechanisms of sodium-dependent hypertension: volume expansion or vasoconstriction? Clin Exp Hypertens A. 1982; 4(4-5):737-49. PMID: 7105437.
    View in: PubMed
  333. Gavras H. Essential hypertension. In: Clinical Hypertension and Hypotension. Brunner HR, Gavras H, eds. Marcel Dekker. New York,NY. 1982.
  334. Clinical Hypertension and Hypotension. Brunner HR, Gavras H: eds. Marcel Dekker Inc. New York,NY. 1982.
  335. Gavras H, Andrews P, Papadakis N. Reversal of experimental delayed cerebral vasospasm by angiotensin-converting enzyme inhibition. J Neurosurg. 1981 Dec; 55(6):884-8. PMID: 6170740.
    View in: PubMed
  336. Burnier M, Turini GA, Brunner HR, Porchet M, Kruithof D, Vukovich RA, Gavras H. RHC 3659: a new orally active angiotensin converting enzyme inhibitor in normal volunteers. Br J Clin Pharmacol. 1981 Dec; 12(6):893-9. PMID: 6280740.
    View in: PubMed
  337. Gavras H, Biollaz J, Waeber B, Brunner HR, Gavras I, Sackel H, Charocopos F, Davies RO. Effects of the oral angiotensin-converting enzyme inhibitor MK-421 in human hypertension. Clin Sci (Lond). 1981 Dec; 61 Suppl 7:281s-283s. PMID: 6274572.
    View in: PubMed
  338. Waeber B, Gavras I, Brunner HR, Gavras H. Safety and efficacy of chronic therapy with captopril in hypertensive patients: an update. J Clin Pharmacol. 1981 Nov-Dec; 21(11-12 Pt 1):508-16. PMID: 6460791.
    View in: PubMed
  339. Hatzinikolaou P, Brecher P, Gavras H. Chronic hypertension increases tyrosine transport across the blood-brain barrier in the rat. Life Sci. 1981 Oct 19; 29(16):1657-60. PMID: 7311712.
    View in: PubMed
  340. Gavras H, Brunner HR, Gavras I. Captopril in the treatment of hypertension. Ann Intern Med. 1981 Oct; 95(4):505-6. PMID: 7025722.
    View in: PubMed
  341. Gavras H, Biollaz J, Waeber B, Brunner HR, Gavras I, Davies RO. Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor "MK-421". Lancet. 1981 Sep 12; 2(8246):543-7. PMID: 6116000.
    View in: PubMed
  342. Creager MA, Halperin JL, Bernard DB, Faxon DP, Melidossian CD, Gavras H, Ryan TJ. Acute regional circulatory and renal hemodynamic effects of converting-enzyme inhibition in patients with congestive heart failure. Circulation. 1981 Sep; 64(3):483-9. PMID: 6266691.
    View in: PubMed
  343. Wauters JP, Waeber B, Brunner HR, Guignard JP, Turini GA, Gavras H. Uncontrollable hypertension in patients on hemodialysis: long-term treatment with captopril and salt subtraction. Clin Nephrol. 1981 Aug; 16(2):86-92. PMID: 6266727.
    View in: PubMed
  344. Black J, Waeber B, Bresnahan MR, Gavras I, Gavras H. Blood pressure response to central and/or peripheral inhibition of phenylethanolamine N-methyltransferase in normotensive and hypertensive rats. Circ Res. 1981 Aug; 49(2):518-24. PMID: 7249286.
    View in: PubMed
  345. Gavras H, Waeber B, Kershaw GR, Liang CS, Textor SC, Brunner HR, Tifft CP, Gavras I. Role of reactive hyperreninemia in blood pressure changes induced by sodium depletion in patients with refractory hypertension. Hypertension. 1981 Jul-Aug; 3(4):441-7. PMID: 7030951.
    View in: PubMed
  346. Liang CS, Yi JM, Sherman LG, Black J, Gavras H, Hood WB. Dobutamine infusion in conscious dogs with and without acute myocardial infarction. Effects on systemic hemodynamics, myocardial blood flow, and infarct size. Circ Res. 1981 Jul; 49(1):170-80. PMID: 7237692.
    View in: PubMed
  347. Hatzinikolaou P, Gavras H, Waeber B, Fisher GH, Ryan JW. Comparative study of three parenteral inhibitors of the angiotensin converting enzyme. Biochem Pharmacol. 1981 Jul 1; 30(13):1869-72. PMID: 6168270.
    View in: PubMed
  348. Hatzinikolaou P, Gavras H, Brunner HR, Gavras I. Role of vasopressin, catecholamines, and plasma volume in hypertonic saline-induced hypertension. Am J Physiol. 1981 Jun; 240(6):H827-31. PMID: 7246746.
    View in: PubMed
  349. Brunner DB, Desponds G, Biollaz J, Keller I, Ferber F, Gavras H, Brunner HR, Schelling JL. Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects. Br J Clin Pharmacol. 1981 May; 11(5):461-7. PMID: 6268131.
    View in: PubMed
  350. Gavras H, Charocopos F, Brunner H, Gavras I. Angiotensin converting enzyme inhibition: a new therapeutic modality. Bull N Y Acad Med. 1981 May; 57(4):304-10. PMID: 6164426.
    View in: PubMed
  351. Biollaz J, Burnier M, Turini GA, Brunner DB, Porchet M, Gomez HJ, Jones KH, Ferber F, Abrams WB, Gavras H, Brunner HR. Three new long-acting converting-enzyme inhibitors: relationship between plasma converting-enzyme activity and response to angiotensin I. Clin Pharmacol Ther. 1981 May; 29(5):665-70. PMID: 6260419.
    View in: PubMed
  352. Textor SC, Gavras H, Tifft CP, Bernard DB, Idelson B, Brunner HR. Norepinephrine and renin activity in chronic renal failure. Evidence for interacting roles in hemodialysis hypertension. Hypertension. 1981 May-Jun; 3(3):294-9. PMID: 7019067.
    View in: PubMed
  353. Faxon DP, Halperin JL, Creager MA, Gavras H, Schick EC, Ryan TJ. Angiotensin inhibition in severe heart failure: acute central and limb hemodynamic effects of captopril with observations on sustained oral therapy. Am Heart J. 1981 May; 101(5):548-56. PMID: 7013458.
    View in: PubMed
  354. Spertini F, Brunner HR, Waeber B, Gavras H. The opposing effects of chronic angiotensin-converting enzyme blockade by captopril on the responses to exogenous angiotensin II and vasopressin vs. norepinephrine in rats. Circ Res. 1981 May; 48(5):612-8. PMID: 6260396.
    View in: PubMed
  355. Textor SC, Brunner HR, Gavras H. Converting enzyme inhibition during chronic angiotensin II infusion in rats. Evidence against a nonangiotensin mechanism. Hypertension. 1981 Mar-Apr; 3(2):269-76. PMID: 6260647.
    View in: PubMed
  356. Gavras I, Gavras H, Tifft CP, Kershaw GR, Bresnahan M. Effect of pindolol on blood pressure, plasma renin activity, and catecholamines in hypertensive patients. J Clin Pharmacol. 1981 Feb-Mar; 21(2):79-83. PMID: 7014658.
    View in: PubMed
  357. Textor SC, Brunner H, Gavras H. Evidence for bradykinin potentiation by angiotensin congeners in conscious rats. Am J Physiol. 1981 Feb; 240(2):H255-61. PMID: 6258451.
    View in: PubMed
  358. Doherty JU, Liang C, Faillace RT, Yi M, Arnold S, Gavras H, Hood WB Jr. Inotropic and chronotropic effects of insulin in the conscious dog: contributions of catecholamines and hypoglycemia. Am J Cardiol. 1981; 47:460.
  359. Brunner HR, Gavras H . Medical therapy of renovascular hypertension. Eighth International Congress of Nephrology, Athens, Zurukzoglu W, Papadimitriou M, Pyrpasopoulos M, Sion M, Zamboulis C, eds. S Karger. Basel. 1981; 1139-1145.
  360. Gavras H, Gavras I, Brunner HR . Clinical relevance of reactive hyperreninemia. Res and Staff Phys. 1981; 27:65-72.
  361. Gavras H, Gavras I . The renin angiotensin system in hypertension. In: Contemporary Issues in Nephrology, Hypertension, Brenner BM, Stein JH, eds. Churchill, Livingston. New York,NY. 1981; 8:65-99.
  362. Brunner HR, Turini GA, Waeber B, Gavras H . Clinical pharmacological studies with captopril. In: Angiotensin Converting Enzyme Inhibitors: Mechanisms of Action and Clinical Implications, Horowitz ZP, ed. Urt and Schwarzenberg. Baltimore. 1981.
  363. Gavras H, Hatzinikolaou P, Brunner HR, Gavras I. Clinical applications of angiotensin blockade. Eighth International Congress of Nephrology, Athens. Zurukzollu W, Pyrpasopoulos M, Sion M, Zamboulis C, eds. S Karger. Basel. 1981; 1060-1066.
  364. Gavras H, Gavras I, Brunner HR . Vasoconstriction and sodium volume factors in renovascular hypertension. In: Frontiers in Hypertension Research, Laragh JH, Buhler F, Seldin DW, eds. Springer-Verlag. New York,NY. 1981; 159-164.
  365. Gavras H, Gavras I, Brunner HR . Hypertension, vasopressors and the susceptibility to vascular injury: experimental and clinical studies. In: Frontiers in Hypertension Research, Laragh JH, Buhler F, Seldin DW, eds. Springer-Verlag. New York,NY. 1981.
  366. Gavras I, Graff LG, Rose BD, McKenna JM, Brunner HR, Gavras H. Fatal pancytopenia associated with the use of captopril. Ann Intern Med. 1981 Jan; 94(1):58-9. PMID: 7004300.
    View in: PubMed
  367. Brunner HR, Waeber B, Turini GA, Wauters JP, Brunner DB, Gavras H. Position paper: angiotensin-converting enzyme blockade as a therapeutic modality. In: Frontiers in Hypertension Research, Laragh JH, F Buhler, Seldin DW, eds. Springer-Verlag. New York,NY. 1981; 503-516.
  368. Waeber B, Brunner HR, Wauters JP, Gavras H. Angiotensin-converting enzyme inhibitors: pathogenic and therapeutic implications for arterial hypertension. Adv Nephrol Necker Hosp. 1981; 10:111-33. PMID: 6267906.
    View in: PubMed
  369. Textor SC, Brunner HR, Gavras H. Converting enzyme inhibition during chronic angiotensin II infusion in rats: evidence against a non-angiotensin mechanism. Clin Sci (Lond). 1980 Dec; 59 Suppl 6:71s-74s. PMID: 6256120.
    View in: PubMed
  370. Brunner HR, Gavras H. Is the renin system necessary? Am J Med. 1980 Nov; 69(5):739-45. PMID: 6254360.
    View in: PubMed
  371. Gavras H, Liang C. Acute renovascular hypertension in conscious dogs. Interaction of the renin-angiotensin system and sympathetic nervous system in systemic hemodynamics and regional blood flow responses. Circ Res. 1980 Sep; 47(3):356-65. PMID: 6157500.
    View in: PubMed
  372. Hatzinikolaou P, Gavras H, Brunner HR, Gavras I. Sodium-induced elevation of blood pressure in the anephric state. Science. 1980 Aug 22; 209(4459):935-6. PMID: 7403861.
    View in: PubMed
  373. Bresnahan MR, Hatzinikolaou P, Brunner HR, Gavras H. Effects of tyrosine infusion in normotensive and hypertensive rats. Am J Physiol. 1980 Aug; 239(2):H206-11. PMID: 7406057.
    View in: PubMed
  374. Brunner HR, Gavras H, Waeber B, Textor SC, Turini GA, Wauters JP. Clinical use of an orally acting converting enzyme inhibitor: captopril. Hypertension. 1980 Jul-Aug; 2(4):558-66. PMID: 6995296.
    View in: PubMed
  375. Gavras I, Gavras H. Special considerations in treating hypertension in the elderly. Geriatrics. 1980 Jul; 35(7):34-40. PMID: 7380255.
    View in: PubMed
  376. Faxon DP, Creager MA, Halperin JL, Gavras H, Coffman JD, Ryan TJ. Central and peripheral hemodynamic effects of angiotensin inhibition in patients with refractory congestive heart failure. Circulation. 1980 May; 61(5):925-30. PMID: 6153939.
    View in: PubMed
  377. Gavras H, Gavras I, Brunner HR. Angiotensin inhibitors for hypertension. Compr Ther. 1980 May; 6(5):14-8. PMID: 6155240.
    View in: PubMed
  378. Kowaloff H, Gavras H, Brecher P. Reninlike enzymatic activity in the cerebral microvessels of the rat. Am J Physiol. 1980 Mar; 238(3):H384-8. PMID: 6989271.
    View in: PubMed
  379. Waeber B, Brunner HR, Brunner DB, Curtet AL, Turini GA, Gavras H. Discrepancy between antihypertensive effect and angiotensin converting enzyme inhibition by captopril. Hypertension. 1980 Mar-Apr; 2(2):236-42. PMID: 6247269.
    View in: PubMed
  380. Gavras H, Gavras I, Hadzinikolaou P, Brunner HR. Inhibition of angiotensin conversion: its role in treatment of hypertension and congestive heart failure. J Cardiovasc Med. 1980; 5:327-335.
  381. Gavras H. Angiotensin inhibition for he characterization and treatment of arterial hypertension. Proceedings of the First Panhellenic Congress of Nephrology, Thessaloniki, March. 1980.
  382. Brunner HR, Gavras H, Waeber B, Turini GA, Wauters JP. Captopril: an oral angiotension converting enzyme inhibitor active in man. Arch Int Pharmacodyn Ther. 1980; Suppl:188-212. PMID: 6251762.
    View in: PubMed
  383. Waeber B, Brunner HR, Gavras H . Les inhibiteurs de l'enzyme de conversion de l'angiotensine: implications pathogeniques et therapeutiques dans l'hypertension arterielle. In: Actualites Nephrologiques de l`Hopital Necker. Flammarion. Belgium. 1980.
  384. Gavras H. B158Congestive heart failure: treatment by angiotensin blockade. Primary Cardiol. 1980; 6:103-113.
  385. Gavras H, Gavras I, Textor S, Tifft CP, Kershaw GR, Brunner HR . The use of SQ 20881 converting enzyme inhibitor (teprotide) for diagnostic purposes in hypertension. In: Captopril and Hypertension. Case D, Sonnenblick E, Laragh JH, eds. Plenum Medical Book Company. New York,NY. 1980; 210-214.
  386. Brunner HR, Waeber B, Gavras H, Brunner DB . Zwechmassige Anwendung von Diuretika in der Behandlung der Arteriellen Hypertonie. In: Diuretika, Rosenthal J, Knauf H, eds. Edition Medizin. Weinheim, Germany. 1980; 307-318.
  387. Brunner HR, Gavras H, Waeber B. Enhancement by diuretics of the antihypertensive action of long-term angiotensin converting enzyme blockade. Clin Exp Hypertens. 1980; 2(3-4):639-57. PMID: 6253243.
    View in: PubMed
  388. Volicer L, Volicer BJ, Gavras H . The effect of alcohol intake on compliance with antihypertensive treatment. In: Alcoholism: A Perspective. Messiha FS, Tyner GS, eds. PJD Publications Ltd. Westbury, New York. 1980; 88-99.
  389. Liang C, Tuttle RR, Hood WB, Gavras H. Conditioning effects of chronic infusions of dobutamine. Comparison with exercise training. J Clin Invest. 1979 Aug; 64(2):613-9. PMID: 457872.
    View in: PubMed
  390. Chobanian AV, Volicer L, Tifft CP, Gavras H, Liang CS, Faxon D. Mineralocorticoid-induced hypertension in patients with orthostatic hypotension. N Engl J Med. 1979 Jul 12; 301(2):68-73. PMID: 449947.
    View in: PubMed
  391. Turini GA, Brunner HR, Gribic M, Waeber B, Gavras H. Improvement of chronic congestive heart-failure by oral captopril. Lancet. 1979 Jun 9; 1(8128):1213-5. PMID: 87679.
    View in: PubMed
  392. Brunner HR, Waeber B, Gavras H. Rational use of captopril. Lancet. 1979 Apr 14; 1(8120):832. PMID: 86084.
    View in: PubMed
  393. Gavras H, Gavras I, Brunner HR, Liang CS. Physiologic studies with saralasin in animals. Kidney Int Suppl. 1979 Mar; (9):S20-8. PMID: 384069.
    View in: PubMed
  394. Volicer L, Liang CS, Gavras H, Tifft CP, Kershaw GR, Gavras I, Griffith DL, Vukovitch R, Brunner HR. Effect of nadolol in treatment of hypertension. J Clin Pharmacol. 1979 Feb-Mar; 19(2-3):137-47. PMID: 33998.
    View in: PubMed
  395. Volicer L, O'Donnell A, Chase A, Gavras H. Cyclic nucleotide levels in brains of control and hypertensive rats. Life Sci. 1979 Jan 8; 24(2):131-5. PMID: 216871.
    View in: PubMed
  396. Gavras I, Gavras H, Sullivan PC, Tifft CP, Chobanian AV, Brunner HR. A comparative study of the effects of oxprenolol versus propranolol in essential hypertension. J Clin Pharmacol. 1979 Jan; 19(1):8-14. PMID: 368088.
    View in: PubMed
  397. Waeber B, Brunner HR, Turini GA, Curtet N, Keller I, Gavras H. [Potentiation of the antihypertensive effect of captopril by diuretics (author's transl)]. Ann Cardiol Angeiol (Paris). 1979 Jan-Feb; 28(1):9-11. PMID: 219758.
    View in: PubMed
  398. Brunner HR, Waiters JP, Waeber B, Gavras H. The renin angiotensin system in hypertensive patients with chronic renal failure. In mitteilungen der Arbeitsgemeinschaft fur Klin. Nephrologie. 1979; 8:4-14.
  399. Tifft CP, Gavras H, Kershaw GR, Gavras I, Brunner HR, Liang CS, Chobanian AV. Converting enzyme inhibition in hypertensive emergencies. Ann Intern Med. 1979 Jan; 90(1):43-7. PMID: 420460.
    View in: PubMed
  400. Brunner HR, Gavras H, Waeber B, Turini GA, McKinstry DN, Vukovich RA, Gavras I. Orally active angiotensin-converting enzyme inhibitor (SO 14,225) as a treatment for essential hypertension. Br J Clin Pharmacol. 1979; 7 Suppl 2:205S-211S. PMID: 223614.
    View in: PubMed
  401. Wauters JP, Waeber B, Brunner HR, Turini GA, Guignard JP, Gavras H. Captopril and salt subtraction to treat "uncontrollable" hypertension in haemodialysis patients. Proc Eur Dial Transplant Assoc. 1979; 16:610-7. PMID: 232915.
    View in: PubMed
  402. Gavras H, Gavras I, Brunner HR . Converting enzyme inhibition in the diagnosis and treatment of hypertension. In: Controversies in Nephrology - Schreiner GE, Winchester JF, Mattern W, Mendelson BF, eds. Washington DC. 1979; 1:260-268.
  403. Brunner HR, Gavras H, Waeber B, Kershaw GR, Turini GA, Vukovich RA, McKinstry DN, Gavras I. Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients. Ann Intern Med. 1979 Jan; 90(1):19-23. PMID: 217289.
    View in: PubMed
  404. Gavras I, Gavras H, Brunner HR, Liang CS. Antihypertensive action of beta-adrenoceptor blockade and the renin-angiotensin system. Br J Clin Pharmacol. 1979; 7 Suppl 2:213S-217S. PMID: 37876.
    View in: PubMed
  405. Brunner HR, Waeber B, Ferguson RK, Turini GA, Gavras H. The position of beta-blockers in antihypertensive therapy. Comparison with other antihypertensive agents. Cardiology. 1979; 64 Suppl 1:88-95. PMID: 42489.
    View in: PubMed
  406. Waeber B, Gavras H, Brunner HR, Chappuis P, Turini GA. [Chronic treatment of hypertension by an inhibitor of angiotensin converting enzyme]. Schweiz Med Wochenschr. 1978 Dec 9; 108(49):1981-3. PMID: 219469.
    View in: PubMed
  407. Liang CS, Gavras H, Brunner HR. Redistribution of regional blood flow after administration of saralasin in salt-depleted dogs. Clin Sci Mol Med Suppl. 1978 Dec; 4:243s-246s. PMID: 282061.
    View in: PubMed
  408. Brunner HR, Gavras H, Turini GA, Waeber B, Cappuis P, McKinstry DN. Long-term treatment of hypertension in man by an orally active angiotensin-converting enzyme inhibitor. Clin Sci Mol Med Suppl. 1978 Dec; 4:293s-295s. PMID: 215374.
    View in: PubMed
  409. Chobanian AV, Gavras H, Melby JC, Gavras I, Jick H. Relationship of basal plasma noradrenaline to blood pressure, age, sex, plasma renin activity and plasma volume in essential hypertension. Clin Sci Mol Med Suppl. 1978 Dec; 4:93s-96s. PMID: 282107.
    View in: PubMed
  410. Jaeger P, Brunner HR, Turini GA, Jéquier E, Ferguson RK, Gavras H. [Long-term minoxidil therapy: renin, aldosterone, noradrenaline and the need for beta blockers]. Schweiz Med Wochenschr. 1978 Nov 4; 108(44):1707-9. PMID: 715407.
    View in: PubMed
  411. Gavras H, Faxon DP, Berkoben J, Brunner HR, Ryan TJ. Angiotensin converting enzyme inhibition in patients with congestive heart failure. Circulation. 1978 Nov; 58(5):770-6. PMID: 699246.
    View in: PubMed
  412. Liang CS, Gavras H. Renin-angiotensin system inhibition in conscious dogs during acute hypoxemia. Effects on systemic hemodynamics, regional blood flows, and tissue metabolism. J Clin Invest. 1978 Nov; 62(5):961-70. PMID: 711860.
    View in: PubMed
  413. Brecher P, Tercyak A, Gavras H, Chobanian AV. Peptidyl dipeptidase in rabbit brain microvessels. Biochim Biophys Acta. 1978 Oct 12; 526(2):537-46. PMID: 214128.
    View in: PubMed
  414. Turini GA, Brunner HR, Ferguson RK, Rivier JL, Gavras H. Congestive heart failure in normotensive man. Haemodynamics, renin, and angiotensin II blockade. Br Heart J. 1978 Oct; 40(10):1134-42. PMID: 708515.
    View in: PubMed
  415. Brunner HR, Waeber B, Wauters JP, Turin G, McKinstry D, Gavras H. Innappropriate renin secretion unmasked by captopril (SQ 14 225) in hypertension of chronic renal failure. Lancet. 1978 Sep 30; 2(8092 Pt 1):704-7. PMID: 80634.
    View in: PubMed
  416. Chobanian AV, Garvras H, Gavras I, Bresnahan M, Sullivan P, Melby JC. Studies on the activity of the sympathetic nervous system in essential hypertension. J Human Stress. 1978 Sep; 4(3):22-8. PMID: 690418.
    View in: PubMed
  417. Koch-Weser J. Angiotensin converting-enzyme inhibitor in refractory hypertension. N Engl J Med. 1978 Aug 17; 299(7):363-4. PMID: 210382.
    View in: PubMed
  418. Brunner HR, Jaeger P, Ferguson RK, Jequier E, Turini G, Gavras H. Need for beta-blockade in hypertension reduced with long-term minoxidil. Br Med J. 1978 Aug 5; 2(6134):385-8. PMID: 28811.
    View in: PubMed
  419. Jaeger P, Ferguson RK, Brunner HR, Turini GA, Gavras H. Relationships of renin and aldosterone to antihypertensive effects of spironolactone and propranolol. J Clin Pharmacol. 1978 Jul; 18(7):311-8. PMID: 353088.
    View in: PubMed
  420. Gavras H, Brunner HR, Turini GA, Kershaw GR, Tifft CP, Cuttelod S, Gavras I, Vukovich RA, McKinstry DN. Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man. N Engl J Med. 1978 May 4; 298(18):991-5. PMID: 205788.
    View in: PubMed
  421. Turini GA, Brunner HR, Ferguson RK, Rivier JL, Gavras H. Angiotensin II blockade in congestive heart failure. Arch Int Pharmacodyn Ther. 1978 May; 233(1):166-76. PMID: 686905.
    View in: PubMed
  422. Jaeger P, Ferguson RK, Brunner HR, Kirchertz EJ, Gavras H. Mechanism of blood pressure reduction by teprotide (SQ 20881) in rats. Kidney Int. 1978 Apr; 13(4):289-96. PMID: 651128.
    View in: PubMed
  423. Liang CS, Gavras H, Hood WB. Renin-angiotensin system inhibition in conscious sodium-depleted dogs. Effects on systemic and coronary hemodynamics. J Clin Invest. 1978 Apr; 61(4):874-83. PMID: 659580.
    View in: PubMed
  424. Gavras H, Gavras I, Textor S, Volicer L, Brunner HR, Rucinska EJ. Effect of angiotensin converting enzyme inhibition on blood pressure, plasma renin activity and plasma aldosterone in essential hypertension. J Clin Endocrinol Metab. 1978 Feb; 46(2):220-6. PMID: 220274.
    View in: PubMed
  425. Liang C, Gavras H, Hood W. Systemic and coronary hemodynamic effect of renin-angiotensin system inhibition in sodium depleted dogs. Amer J Cardiol. 1978; 41:394.
  426. Chobanian AV, Gavras H, Melby JC, Gavras I, Jick H. Relationship of basal plasma norepinephrine to blood pressure, plasma renin activity, mineralocorticoids, and plasma volume in essential hypertension. Trans Assoc Am Physicians. 1978; 91:368-80. PMID: 754399.
    View in: PubMed
  427. Jaeger P, Ferguson RK, Brunner GR, Turini GA, Gavras H, Brunner HR . La tension arterielle, la renine et l'aldosterone au cours d'un essay controle avec la spironolactone et le propranolol, seuls et en association. La Revue de Medicine. 1978; 19:45-51.
  428. Gavras H, Gavras I. Angiotensin inhibition: a new approach to the treatment of hypertension. Iatriki. 1978; 34:521-525.
  429. Gavras H, Gavras I, Cannon PJ, Brunner HR, Laragh JH. Is elevated plasma renin activity of prognostic importance in progressive systemic sclerosis? Arch Intern Med. 1977 Nov; 137(11):1554-8. PMID: 921442.
    View in: PubMed
  430. Gavras H, Flessas A, Ryan TJ, Brunner HR, Faxon DP, Gavras I. Angiotensin II inhibition. Treatment of congestive cardiac failure in a high-renin hypertension. JAMA. 1977 Aug 22; 238(8):880-2. PMID: 577978.
    View in: PubMed
  431. Gavras H, Gavras I, Brunner HR, Laragh JH. The antihypertensive action of methyldopa in relation to its effect on the renin-aldosterone system. J Clin Pharmacol. 1977 Jul; 17(7):372-8. PMID: 881470.
    View in: PubMed
  432. Gavras H, Gavras I, Brunner HR, Laragh JH. Effect of a new beta-adrenergic blocker, l-bunolol, on blood pressure and on the renin-aldosterone system. J Clin Pharmacol. 1977 May-Jun; 17(5-6):350-7. PMID: 323300.
    View in: PubMed
  433. Ferguson RK, Turini GA, Brunner HR, Gavras H, McKinstry DN. A specific orally active inhibitor of angiotensin-converting enzyme in man. Lancet. 1977 Apr 9; 1(8015):775-8. PMID: 66571.
    View in: PubMed
  434. Posternak L, Brunner HR, Gavras H, Brunner DB. Angiotensin II blockade in normal man: interaction of renin and sodium in maintaining blood pressure. Kidney Int. 1977 Mar; 11(3):197-203. PMID: 846071.
    View in: PubMed
  435. Brunner HR, Gavras H. Vascular damage in hypertension. In: Hypertension: Mechanisms, Diagnosis and Management, Davis JO, Laragh JH, Selwyn A, eds. HP Publishing Co. New York,NY. 1977; 169-180.
  436. Jaeger P, Ferguson RK, Brunner HR, Gavras H . Comparison of SQ 20881 and saralasin in normotensive and hypertensive rats. Kidney Int. 1977; 12:75.
  437. Brunner HR, Gavras H. [Angiotensin II inhibitors for the diagnosis and treatment of hypertension]. Schweiz Med Wochenschr. 1976 Dec 11; 106(50):1791-8. PMID: 1013701.
    View in: PubMed
  438. Gavras H, Ribeiro AB, Gavras I, Brunner HR. Reciprocal relation between renin dependency and sodium dependency in essential hypertension. N Engl J Med. 1976 Dec 2; 295(23):1278-83. PMID: 980059.
    View in: PubMed
  439. Gavras H, Ribeiro A, Brunner HR, Gavras I. Determination of renin-dependency and sodium-dependency in the three renin sub-groups of essential hypertension. Clin Sci Mol Med Suppl. 1976 Dec; 3:197s-200s. PMID: 1071607.
    View in: PubMed
  440. Gavras H, Brunner HR. Letter: Renin profiling in hypertension. N Engl J Med. 1976 Sep 23; 295(13):734. PMID: 958254.
    View in: PubMed
  441. Brunner HR, Gavras H. Les inhibiteurs de l"angiotensine II pour le diagnostic et le traitment de l'hypertension. Schweiz Med Wschr. 1976; 106:1791.
  442. Gavras H, Oliver JA, Cannon PJ. Interrelations of renin, angiotensin II, and sodium in hypertension and renal failure. Annu Rev Med. 1976; 27:485-521. PMID: 779610.
    View in: PubMed
  443. Brunner HR, Gavras H, Ribeiro AB, Posternak L. Angiotensin II blockade in normal man and patients with essential hypertension. Blood pressure effects depending on renin and sodium balance. Prog Biochem Pharmacol. 1976; 12:145-62. PMID: 1019161.
    View in: PubMed
  444. Brunner HR, Gavras H. Pathophysiological concepts of renovascular hypertension. Contrib Nephrol. 1976; 3:20-9. PMID: 1026366.
    View in: PubMed
  445. Vaughan ED, Bühler FR, Laragh JH, Sealey JE, Gavras H, Baer L. Hypertension and unilateral parenchymal renal disease. Evidence for abnormal vasoconstriction-volume interaction. JAMA. 1975 Sep 15; 233(11):1177-83. PMID: 1174172.
    View in: PubMed
  446. Brunner HR, Gavras H. Clinical implications of renin in the hypertensive patient. JAMA. 1975 Sep 8; 233(10):1091-3. PMID: 1174160.
    View in: PubMed
  447. Gavras H, Oliver N, Aitchison J, Begg C, Briggs JD, Brown JJ, Horton PW, Lee F, Lever AF, Prentice C, Robertson JI. Abnormalities of coagulation and the development of malignant phase hypertension. Kidney Int Suppl. 1975 Sep; S252-61. PMID: 1059805.
    View in: PubMed
  448. Gavras H, Brunner HR, Thurston H, Laragh JH. Reciprocation of renin dependency with sodium volume dependency in renal hypertension. Science. 1975 Jun 27; 188(4195):1316-7. PMID: 1145199.
    View in: PubMed
  449. Gavras H, Brunner HR, Laragh JH, Gavras I, Vukovich RA. The use of angiotensin-converting enzyme inhibitor in the diagnosis and treatment of hypertension. Clin Sci Mol Med Suppl. 1975 Jun; 2:57s-60s. PMID: 1077792.
    View in: PubMed
  450. Gavras H, Kremer D, Brown JJ, Gray B, Lever AF, MacAdam RF, medina A, Morton JJ, Robertson JI. Angiotensin- and norepinephrine-induced myocardial lesions: experimental and clinical studies in rabbits and man. Am Heart J. 1975 Mar; 89(3):321-32. PMID: 234666.
    View in: PubMed
  451. Gavras H, Brunner HR, Laragh JH, Vaughan ED, Koss M, Cote LJ, Gavras I. Malignant hypertension resulting from deoxycorticosterone acetate and salt excess: role of renin and sodium in vascular changes. Circ Res. 1975 Feb; 36(2):300-9. PMID: 234807.
    View in: PubMed
  452. Laragh JH, Sealey JE, Bühler FR, Vaughan ED, Brunner HR, Gavras H, Baer L. The renin axis and vasoconstriction volume analysis for understanding and treating renovascular and renal hypertension. Am J Med. 1975 Jan; 58(1):4-13. PMID: 234677.
    View in: PubMed
  453. Brunner HR, Gavras H . Vascular damage in hypertension. Hospital Practice. 1975; 10:97-108.
  454. Brunner HR, Gavras H. Sodium dependent hypertension. Medcom. 1975.
  455. Brunner HR, Gavras H. The role of renin and sodium in high blood pressure regulation. In: Pathophysiology and management of arterial hypertension. Berglund G, Hansson I, Werko L, eds. AB Hassle. Molndel, Sweden. 1975; 32-44.
  456. Paton AM, Lever AF, Oliver NW, Medina A, Briggs JD, Morton JJ, Brown JJ, Robertson JI, Fraser R, Tree M, Gavras H. Plasma angiotensin II, renin, renin-substrate and aldosterone concentrations in acute renal failure in man. Clin Nephrol. 1975 Jan; 3(1):18-23. PMID: 1126059.
    View in: PubMed
  457. Gavras H, Oliver N, Brown JJ, Aitchison J, Briggs JD, Lee F, Lever AF, Robertson JIS . Microangiopathic hemolytic anemia and the pathogenesis of malignant hypertension. Kidney Int. 1975; 8:S-252.
  458. Gavras H, Brunner HR, Laragh JH, Sealey JE, Gavras I, Vukovich RA. An angiotensin converting-enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients. N Engl J Med. 1974 Oct 17; 291(16):817-21. PMID: 4371298.
    View in: PubMed
  459. Brunner HR, Gavras H. [Renin and sodium in blood pressure regulation]. Schweiz Med Wochenschr. 1974 Oct 5; 104(40):1401-11. PMID: 4376263.
    View in: PubMed
  460. Gavras H, Brunner HR. [Renin and sodium and the formation of vascular lesions in hypertension]. Schweiz Med Wochenschr. 1974 Sep 21; 104(38):1301-10. PMID: 4371116.
    View in: PubMed
  461. Brunner HR, Gavras H, Laragh JH. Specific inhibition of the renin-angiotensin system: A key to understanding blood pressure regulation. Prog Cardiovasc Dis. 1974 Sep-Oct; 17(2):87-98. PMID: 4369198.
    View in: PubMed
  462. Gavras H, Brunner HR, Gavras I, Laragh JH. Letter: Hypotensive effect of angiotensin-converting-enzyme inhibitor SQ 20,881. Lancet. 1974 Aug 10; 2(7876):353. PMID: 4136088.
    View in: PubMed
  463. Gavras H, Brunner HR, Laragh JH. Renin and aldosterone and the pathogenesis of hypertensive vascular damage. Prog Cardiovasc Dis. 1974 Jul-Aug; 17(1):39-49. PMID: 4365952.
    View in: PubMed
  464. Vaughan ED Jr, Laragh JH, Gavras I, Buhler FR, Gavras H, Brunner HR, Baer L . The volume factor in low and normal renin essential hypertension. Its treatment with either spironolactone or chlorothalidone. In Hypertension Manual, Laragh JH, ed. Dunn-Donnelly Publ Co. New York,NY. 1974; 851-871.
  465. Buhler FR, Laragh JH, Vaughan ED Jr, Brunner HR, Gavras H, Baer L. The antihypertensive action of propranolol: specific anti-renin responses in high and normal renin forms of essential, renal, renovascular and malignant hypertension. In: Hypertension Manual, Laragh JH, ed. Dunn-Donnelly Publ Co. New York,NY. 1974; 873-989.
  466. Brunner HR, Gavras H, Laragh JH. Angiotensin-II blockade in man by sar1-ala8-angiotensin II for understanding and treatment of high blood-pressure. Lancet. 1973 Nov 10; 2(7837):1045-8. PMID: 4127309.
    View in: PubMed
  467. Bühler FR, Laragh JH, Vaughan ED, Brunner HR, Gavras H, Baer L. Antihypertensive action of propranolol. Specific antirenin responses in high and normal renin forms of essential, renal, renovascular and malignant hypertension. Am J Cardiol. 1973 Sep 20; 32(4):511-22. PMID: 4729721.
    View in: PubMed
  468. Vaughan ED, Laragh JH, Gavras I, Bühler FR, Gavras H, Brunner HR, Baer L. Volume factor in low and normal renin essential hypertension. Treatment with either spironolactone or chlorthalidone. Am J Cardiol. 1973 Sep 20; 32(4):523-32. PMID: 4729722.
    View in: PubMed
  469. Oliver N, Gavras H, Aitchison J, Begg C, Briggs JD, Brown JJ, Horton PW, Lee F, Lever AF, Prentice C, Robertson JI. Microangiopathic haemolytic anaemia in malignant phase hypertension. Br Heart J. 1973 Aug; 35(8):863. PMID: 4729850.
    View in: PubMed
  470. Gavras H, Brunner HB, Vaughan ED, Laragh JH. Angiotensin-sodium interaction in blood pressure maintenance of renal hypertensive and normotensive rats. Science. 1973 Jun 29; 180(4093):1369-71. PMID: 4350930.
    View in: PubMed
  471. Vaughan ED, Gavras H, Laragh JH, Koss MN. Vascular permeability factor: dissociation from the angiotensin II induced pressor and drinking responses. Nature. 1973 Mar 30; 242(5396):334-5. PMID: 4349236.
    View in: PubMed
  472. Brown JJ, Gavras H, Kremer D, Lever AF, MacGregor J, Powell-Jackson JD, Robertson JIS. Renin and acute renal failure. Proceedings of Conference on Acute Renal Failure, State University of New York, Downstate Medical Center. Washington, D.C.: U.S. Government Printing Office. 1973; 57.
  473. Lawson DH, Macadam RF, Singh MH, Gavras H, Hartz S, Turnbull D, Linton AL. Effect of furosemide on antibiotic-induced renal damage in rats. J Infect Dis. 1972 Dec; 126(6):593-600. PMID: 4664116.
    View in: PubMed
  474. Leckie B, Gavras H, McGregor J, McElwee G. The conversion of angiotensin I to angiotensin II by rabbit glomeruli. J Endocrinol. 1972 Oct; 55(1):229-30. PMID: 4350083.
    View in: PubMed
  475. Papapetrou PD, Marchant B, Gavras H, Alexander WD. Biliary excretion of 35 S-labelled propylthiouracil, methimazole and carbimazole in untreated and pentobarbitone pretreated rats. Biochem Pharmacol. 1972 Feb 1; 21(3):363-77. PMID: 4111354.
    View in: PubMed
  476. MacGregor J, Briggs JD, Brown JJ, Chinn RC, Gavras H, Lever AF, MacAdam RF, Medina A, Morton JJ, Oliver NWJ, Paton A, Powell-Jackson JD, Robertson JIS Waite MA. Renin and renal function. International Congress Series #268. Modern Diuretic Therapy in the Treatment of Cardiovascular and Renal Disease. Amsterdam: Excerpta Medica. 1972; 71.
  477. Brown WC, Brown JJ, Gavras H, Jackson A, Lever AF, McGregor J, MacAdam RF, Robertson JI. Renin and acute circulatory renal failure in the rabbit. Circ Res. 1972 Jan; 30(1):114-22. PMID: 5007522.
    View in: PubMed
  478. Brown JJ, Chinn RH, Gavras H, Leckie B, Lever AF, MacGregor J, Morton J, Robertson JIS . Renin and renal function. In: Hypertension 1972, Genest J, Koiw E, eds. Springer-Verlag. Berlin. 1972.
  479. Gavras H, Lawson DH, Linton AL. Extended therapy with a trimethoprim-sulphonamide for the treatment of established urinary tract infection. Scott Med J. 1971 Dec; 16(12):506-8. PMID: 4944205.
    View in: PubMed
  480. Gavras H, Lever AF, Brown JJ, Macadam RF, Robertson JI. Acute renal failure, tubular necrosis, and myocardial infarction induced in the rabbit by intravenous angiotensin II. Lancet. 1971 Jul 3; 2(7714):19-22. PMID: 4103665.
    View in: PubMed
  481. Gavras H, Brown WC, Brown JJ, Lever AF, Linton AL, MacAdam RF, McNicol GP, Robertson JI, Wardrop C. Microangipathic hemolytic anemia and the development of the malignant phase of hypertension. Circ Res. 1971 May; 28(5):Suppl 2:127-42. PMID: 5568228.
    View in: PubMed
  482. Brown JJ, Gavras H, Leckie B, Lever AF, MacAdam RF, Morton JJ, Robertson JIS. Acute renal circulatory failure: a probable manifestation of excess renin release. In: Control of Renin Secretion, Assaykeen TA, ed. Plenum Publishing Co. New York,NY. 1971.
  483. Gavras H, Brown JJ, Lever AF, MacAdam RF, Robertson JIS . Angiotensin II and renal failure. Lancet II: (Letter). 1971; 764-765.
  484. Lawson DH, Macadam RF, Singh H, Gavras H, Linton AL. The nephrotoxicity of cephaloridine. Postgrad Med J. 1970 Oct; Suppl:36-9. PMID: 5488206.
    View in: PubMed
  485. Gavras H, Brown JJ, Lever AF, Robertson JI. Changes of renin in individual glomeruli in response to variations of sodium intake in the rabbit. Clin Sci. 1970 Apr; 38(4):409-14. PMID: 5428805.
    View in: PubMed
  486. Brown JJ, Brown WCB, Dusterdieck G, Gavras H, Gleadle RI, Jackson AM, Lawson DH, Lever AF, Linton AL, MacGregor M, MacAdam RF, Prentice E, Robertson JIS, Tree M. Renin and acute renal failure. Eur J Clin Invest. 1970; 1:127.
  487. Linton AL, Gavras H, Gleadle RI, Hutchison HE, Lawson DH, Lever AF, Macadam RF, McNicol GP, Robertson JI. Microangiopathic haemolytic anaemia and the pathogenesis of malignant hypertension. Lancet. 1969 Jun 28; 1(7609):1277-82. PMID: 4182177.
    View in: PubMed
  488. Melleissinos K, Gavras H, Danopoulos E . Thrombocytopenia in the liver cirrhosis resembling idiopathic-thrombocytopenic purpura (Werlhof's disease). Nosokomiaka Chron. 1969; 31:379.
  489. Yatzidis H, Gavras H. The diagnostic value of the different tests in hypertension renal vascular disease. Nosokomiaka Chron. 1968; 30:33-45.
  490. Gavras H. The value of different tests in the diagnosis of occlusive renal artery hypertension (clinical and laboratory studies of 29 cases). Thesis, Athens University. 1967.
  491. YATZIDIS H, OREOPOULOS D, TRIANTAPHYLLIDIS D, VOUDICLARI S, TSAPARAS N, GAVRAS C, STAVROULAKI A. TREATMENT OF SEVERE BARBITURATE POISONING. Lancet. 1965 Jul 31; 1(7405):216-7. PMID: 14315232.
    View in: PubMed
  492. Gavras H. Result of the U.S. Hypertension Report Card.
Haralambos's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
BU Co-Authors
_
Similar BU People
_
Same Department